raport de autoevaluare perioada: 1 iulie 2005- …...(lista brevetelor si cit ărilor, grupate pe...

1

RAPORT DE AUTOEVALUARE

perioada: 1 iulie 2005- 30 iunie 2010

1. Datele de autentificare ale unităţii de cercetare-dezvoltare

1.1. Denumirea: INSTITUTUL ONCOLOGIC “Prof. Dr. I. CHIRICUTA” CLUJ-NAPOCA

1.2. Statutul Juridic1): Unitate Sanitara – Institut cu Personalitate Juridica - INSTITUTUL

ONCOLOGIC “Prof. Dr. I. CHIRICUTA” CLUJ-NAPOCA

1.3. Actul de infiintare2): Hotărârea de Guvern Nr. 144/2010

1.4. Numărul de înregistrare in Registrul potenţialilor contractori:1428

1.5. Manager : Conf.Dr. Alexandru Irimie

1.6. Adresa: Republicii 34-36, CLUJ NAPOCA

1.7. Telefon, fax, pagina web, e-mail: 0264-598361; 0264-598365; www.iocn.ro ,

[email protected]

2. Domeniul de specialitate

2.1. Conform clasificării UNESCO3): 3289

2.2. Conform clasificării CAEN: principal 8610 ; secundar 7310

3. Starea unităţii de cercetare-dezvoltare

3.1. Misiunea unităţii de cercetare-dezvoltare, direcţiile de cercetare, dezvoltare, inovare:

(maximum 1.000 de caractere):

Viziunea noastră este de a contribui substanţial la ameliorarea tratamentelor

oncologice prin integrarea activităţii de cercetare fundamentală aplicativă cu cercetarea şi

practica clinică.

Misiunea Departamentului de cercetare ştiinţifică este de a planifica, proiecta şi pune

în practică strategii menite a asigura un nivel ridicat de performanţă al cercetării ştiinţifice în

Institutul Oncologic “Prof. Dr. Ion Chiricuţă”, în context naţional şi internaţional.

Direcţiile principale de acţiune ale Departamentului de cercetare ştiinţifică sunt:

a. promovarea excelenţei în cercetare;

2

b. modernizarea şi eficientizarea bazei materiale a cercetării ştiinţifice din Institut

c. orientarea cercetării din Institutul Oncologic “Prof. Dr. Ion Chiricuţă” spre

nevoile pe termen mediu şi lung ale specialităţilor medicale implicate în

tratamentul cancerului şi pe un plan mai general ale societăţii noastre.

d. realizarea unui management eficient şi eficace al activităţii de cercetare

ştiinţifică

e. întărirea dimensiunii cooperării internaţionale

f. crearea unui climat de încredere şi cooperare ştiinţifică între cercetătorii IOCN

cadrele didactice ale UMF Cluj care lucrează cu integrare clinică în Institut,

ceilalţi specialişti, bazat pe transparenţă decizională

g. dimensiunea educaţională: atragerea de cercetători tineri şi formarea acestora

pentru a deveni competitivi pe plan naţional şi internaţional

h. evaluarea periodică a rezultatelor cercetării ştiinţifice şi a centrelor de cercetare

ştiinţifică existente în Institut.

Aceste direcţii de acţiune au în vedere creşterea relevanţei cercetării ştiinţifice în Institutul

Oncologic “Prof. Dr. Ion Chiricuţă”, promovarea acesteia pe plan naţional şi internaţional şi

integrarea cercetării ştiinţifice în aria cercetării europene.

3.2. Modul de valorificare a rezultatelor de cercetare, dezvoltare, inovare si gradul de

recunoaştere a acestora (maximum 1.000 de caractere):

Cercetarea în oncologie are un pronunţat caracter multidisciplinar. Valorificarea rezultatelor

cercetării de laborator este posibilă prin translaţia acestora în practica clinică cu scopul de a

individualiza tratamentele şi de a introduce metode terapeutice noi. Deasemenea cercetarea

clinică (studiile clinice) este cea care validează pe plan practic valoarea diferitelor tratamente.

Institutul este partener la numeroase studii clinice, iar unele dintre aceste sunt iniţiate chiar în

Institut. Ne propunem creşterea progresivă a numărului de pacienţi care sunt trataţi în studii

clinice ca un indicator al performanţei sectorului de cercetare şi creşterea ponderii

cunoştinţelor care să facă obiectul transferului din „laborator la patul bolnavului”.

3

Recunoaşterea acestor rezultate trebuie concretizată prin creşterea numărului de publicaţii în

reviste cotate pe plan naţional şi mai ales internaţional.

3.3. Situaţia financiara - datorii la bugetul de stat:

NU SUNT

4. Criterii primare de performanta

punctaj

4.1. Lucrări ştiinţifice/tehnice publicate in reviste de

specialitate cotate ISI4)

4.1.1. Număr de lucrări ştiinţifice 84 x 30 =2520

4.1.2. Punctaj cumulat ISI5) 324.714 x 5= 1623.57

4.1.3. Număr de citări in reviste de specialitate cotate ISI6) 4031x 5 = 20155

(Lista lucrărilor si citărilor, grupate pe ani, se ataşează ca anexa nr. 4.1)

Total punctaj cap. 4.1: 24298.57

4.2. Brevete de inventie7)

4.2.1. Număr de brevete x 30

4.2.2. Număr de citări de brevete in sistemul ISI x 5

(Lista brevetelor si citărilor, grupate pe ani, se ataşează ca anexa nr. 4.2)

Total punctaj cap. 4.2: 0

4.3. Produse si tehnologii rezultate din activitati de cercetare, bazate pe brevete, omologări

sau inovaţii proprii. Studii prospective si tehnologice si servicii rezultate din activitatea de

cercetare-dezvoltare, comandate de beneficiar

(Se indica contractul si firma care utilizează produsul, serviciul si tehnologia).

4.3.1. Număr de produse, tehnologii, studii, servicii 11 x 20 = 220

(Lista produselor, serviciilor si tehnologiilor, grupate pe ani, se ataşează

ca anexa nr. 4.3)


Total punctaj cap. 4: 24518.57

4

5. Criterii secundare de performanta

5.1. Lucrări ştiinţifice (tehnice) publicate in reviste de specialitate8)

fără cotaţie ISI

5.1.1. Număr de lucrări 41 x 5 = 205

(Lista lucrărilor grupate pe ani se ataşează ca anexa nr. 5.1)

Total punctaj cap. 5.1:

5.2. Lucrări ştiinţifice prezentate la conferinţe internaţionale cu comitet de program

5.2.1. Număr de comunicări prezentate 159 x 5 =795

(Lista comunicărilor grupate pe ani se ataşează ca anexa nr. 5.2)

Total punctaj cap. 5.2:

5.3. Modele fizice, modele experimentale, modele funcţionale, prototipuri,normative,

proceduri, metodologii, reglementari si planuri tehnice noi sau perfecţionate, realizate in

cadrul programelor naţionale sau comandate de

beneficiar

5.3.1. Număr de modele, normative, proceduri etc.: 1 x 5 = 5

(Lista modelelor, normativelor etc., grupate pe ani, se ataşează ca anexa nr. 5.3)


Total punctaj cap. 5: 205+795+5=1005

6. Prestigiul profesional

6.1. Membri (incluzând statutul de recenzor) in colectivele de redacţie ale unor reviste (cotate

ISI sau incluse in baze de date internaţionale) sau in colective editoriale ale unor edituri

internaţionale recunoscute

Număr de prezente in perioada pentru care se face evaluarea: 5 x 20=100

Nr. crt. Nume Titlul revistei/editurii

6.2. Membri in colectivele de redacţie ale revistelor recunoscute naţional (din categoria B in

clasificarea CNCSIS)

Număr de prezente: 1 x 10=10

5

Nr. crt. Nume Titlul revistei/editurii

6.3. Premii internaţionale obţinute printr-un proces de selecţie

Anexa 6.3

Număr de premii: 7 x 20 = 140

Nr. crt. Nume Premiul Anul

6.4. Premii naţionale ale Academiei Romane

Număr de premii: x 20

Nr. crt. Nume Premiul Anul

6.5. Conducători de doctorat, membri ai unităţii de cercetare

Număr de conducători de doctorat: x 10

Nr. crt. Nume

6.6. Număr de doctori in ştiinţa, membri ai unităţii de cercetare

Număr de doctori in ştiinţa: 10 x 10 = 100

Total punctaj cap. 6:100+10+140+100=350

Total punctaj cap. 4+5+6: 24518.57+1005+350=25873.57

7. Venituri realizate prin contracte de cercetare in domeniul pentru care se face evaluarea (in

perioada pentru care se face evaluarea):

7.1. Numărul si valoarea contractelor de cercetare internaţionale finanţate din fonduri

publice9):

7.2. Numărul si valoarea contractelor de cercetare internaţionale finanţate din fonduri

private:

7.3. Numărul si valoarea contractelor de cercetare naţionale finanţate din fonduri publice10):

an Nr.

proiecte

tip program Valoare in

RON pe an

Valoare

totala RON

pe an

Valoare

totala in

EUR pe an

2005 8 1 - grant

4 – CEEX VIASAN

3 -PNCD I VIASAN

2.000

167.500

229.960

399.460

114.131,43

6

2006 27 2 granturi

22 CEEX VIASAN, CNMP

3 PNCD I VIASAN

69.000

1265.828

188.880

1.523.708

435.345,14

2007 34 1 PNCD II CNCSIS

23 CEEX

3 PNCD I VIASAN

7 PNCD II – Pr 4

99.000

2103.892

136.880

303.185

2.642.957

755.130,57


17 CEEX

3 PNCD I VIASAN

14 PNCD II – PR IV

374.000

3.099.308

75.000

1.174.327

4.722.635 1.185.043,4

1


14 PNCD II – PR IV

288.221

701.806

990.027

234.148,57

TOTAL 10.278.787,0

0

2.723.799,1

2

7.4. Numărul si valoarea contractelor de cercetare naţionale finanţate din fonduri private:

7.5. Alte surse:

7 bis. Venituri realizate din activităţi economice (servicii, microproducţie):

8. Resursa umana de cercetare

8.1. Total personal de cercetare care realizează venituri din activitatea de cercetare-

dezvoltare/din care doctori in ştiinţa:

8.1.1. Cercetători ştiinţifici gradul 1 (profesori)/din care doctori in ştiinţa: 3/3

8.1.2. Cercetători ştiinţifici gradul 2 (conferenţiari)/din care doctori in ştiinţa: 6/6

8.1.3. Cercetători ştiinţifici gradul 3 (lectori)/din care doctori in ştiinţa: 1/1

8.1.4. Cercetători ştiinţifici/din care doctori in ştiinţa: 3/0

8.1.5. Asistenţi de cercetare: 4/1

8.1.6. Total personal auxiliar de cercetare angajat: 18

7

8.2. Date privind perfecţionarea resursei umane

8.2.1. Număr de doctoranzi si masteranzi care lucrează in unitatea de cercetare-dezvoltare la

data completării formularului: 8

8.2.2. Număr de teze de doctorat realizate in unitatea de cercetare-dezvoltare in perioada

pentru care se face evaluarea:13

9. Infrastructura de cercetare-dezvoltare

9.1. Laboratoare de cercetare-dezvoltare:

ORGANIGRAMA IN ANEXA

9.2. Lista echipamentelor performante achiziţionate in ultimii 10 ani:

Nr. crt. Echipamentul Anul fabricaţiei Valoarea Sursa de finanţare a investiţiei

Nr.

crt.

Echipament Anul

achiziţionării

Valoarea Sursa de

finanţare a

investiţiei

1 Sistem HPLC 2001 155.905,72 Grant Banca

Mondiala UMF

(custodie IOCN)

2 Secventiator automat 2001 140.335,1 Grant Banca

Mondiala UMF

(custodie IOCN)

3 Centrifuga de laborator 2001 10.153,83 Grant Banca

Mondiala UMF

(custodie IOCN)

4 Procesor Vysis VP2000 2001 69.277 Grant Banca

Mondiala UMF

(custodie IOCN)

5 Analizator de imagini pt

electr.

2001 45.116,23 Grant Banca

Mondiala UMF

8

(custodie IOCN)

6 Spectrofotometru UV cu db 2001 40.497,66 Grant Banca

Mondiala UMF

(custodie IOCN)

7 Sistem imobilizare 2001 3.937,59 Grant Banca

Mondiala UMF

(custodie IOCN)

8 Celula de transfer pt statting 2001 18.839,24 Grant Banca

UMF (custodie

IOCN)Mondiala

9 Instalatie de Electroforeza

medicala

2001 43.439,01 Grant Banca

Mondiala UMF

(custodie IOCN)

10 Sistem de analiza automata 2001 203.062,02 Grant Banca

Mondiala UMF

(custodie IOCN)

11 Centrifuga universala cu

acces

2001 48.563,54 Grant Banca

Mondiala UMF

(custodie IOCN)

12 Hota in flux laminar 2001 16.691,33 Grant Banca

Mondiala UMF

(custodie IOCN)

13 Sistem de analiza a imaginii 2002 141.937,72 Grant Banca

Mondiala UMF

(custodie IOCN)

14 Sistem Electroforeza 2002 71.232,75 Grant Banca

Mondiala UMF

(custodie IOCN)

15 Sistem pt microfotografiere 2002 76.893,60 Grant Banca

9

Mondiala UMF

(custodie IOCN)

16 Microscop E 1000 Nikon 2002 134.563,8 Grant Banca

Mondiala UMF

(custodie IOCN)

17 Hota HH 1-2 Plus 2002 16.843,01 Grant Banca

Mondiala UMF

(custodie IOCN)

18 Incubator 2002 14.393,87 Grant Banca

Mondiala UMF

(custodie IOCN)

19 Cititor Elisa cu spalator 2002 23.748,81 Grant Banca

Mondiala UMF

(custodie IOCN)

20 Analizor de citometrie cu

acces...

2003 184.725,41 Chelt generale

universitare UMF

(custodie IOCN)

21 Masa chirurgicala cu acesorii 2005 64.092,21 Cercetare MEC

22 Trusa chirurgie laparoscopica 2005 150.854,16 Cercetare MEC

23 Monitor pacient MEC 1000 2005 11.109 Cercetare MEC



26 Sistem PCR 96 WELL 2006 21.658 Cercetare MEC

27 Hota bacteriologica Lamil

Plus 16

2006 23.389,45 Cercetare MEC

28 Upgrade sistem de stocare si

transmisie imagini

2006 27.000 Cercetare MEC

29 Incubator cu CO2 2006 32.487 Cercetare MEC

30 Incubator cu CO2 2006 23.431,5 Cercetare MEC

10

31 Spectrofotometru UV VIS

(sistem analiza nanodrop)


32 Centrifuga Universal 320R cu

racire


33 Hota bacteriologica lamil plus

10


34 Omogenizator (procesor ) cu

ultrasunete


35 Aparat fabricat fulgi de

gheata

2007 11426 CNCSIS

36 Criocauter cu acesorii 2007 22.201,83 Cercetare MEC

37 Electrocauter MBC 600 2007 21.082,27 Cercetare MEC

38 Electrocauter seria 78377 2007 20.675,31 Cercetare MEC

39 Statie includere la parafina 2007 31.502,16 Cercetare MEC

40 Aparat de produs gheata

Ziegra


41 Aparat maruntit probe

biologice seria 30208


42 Ultracongelator vertical 440 l,

-86 0 C


43 Vas Dewar azot lichid - rack 2007 16.842,37 Cercetare MEC

44 Vas Dewar azot lichid 2007 9.991,49 Cercetare MEC

45 Traductor endocavitar EC123 2007 27.728,19 Cercetare MEC

46 Balanta analitica cu 5

zecimale si incinta cantarire


47 Hota cu flux laminar Lamil

Plus


48 Aparat foto digital Olympus

E330

2007 15.670 Cercetare MEC

11

49 Dulap rack black 19 ” 2007 17.600 Cercetare MEC

50 Microscop inversat config

completa


51 Separator de celule 2007 8.093,74 Cercetare MEC

52 Vas Dewar 10 l 2007 3.690,73 Cercetare MEC

53 Microtom RM 2125 2007 21.227,42 Cercetare MEC

54 Microtom RM 2125 2007 21.227,42 Cercetare MEC

55 Statie de lucru GROSSLAB SR 2007 66.000 Cercetare MEC

56 Centrifuga cu racire

MIKRO200R


57 Electroporator 2007 18.772,25 Cercetare MEC

58

Microscop pt.analize

histologice 2007 14.385,67

Cercetare MEC

59

Sistem siguranta Back-up

CO2 2007 5.287,17

Cercetare MEC

60 Autostainer 2007 162.292,53 Cercetare MEC

61

Sursa de lumina pt.lupe

operatorii 2007 6.506,85

Cercetare MEC

62 Hota de culturi clasa a II-a 2007 17.600,85 Cercetare MEC

63 Etuva de laborator - pupinel 2007 3.803,24 Cercetare MEC

64 Camera foto NIKON 2007 6.479,55 Cercetare MEC

65 Lupe operatorii 2007 7.282,80 Cercetare MEC

66 Infusomat FMS 2007 5.569,20 Cercetare MEC

67 Centrifuga cu racire 2007 14.137,20 Cercetare MEC

68 Placa sofanta 2007 2.817,09 Cercetare MEC

69 Balanta analitica cu 5 zec. 2007 3.516,39 Cercetare MEC

70 Hota laminara 2007 12.643,94 Cercetare MEC

71 Dozimetru personal digital 2007 6.479,55 Cercetare MEC

12

72 Microscop inversat motorizat 2007 170.635,29 Cercetare MEC

73 Cititor de microplaci 2008 135.656,43 Cercetare MEC

74

Geldoc XR System (Sistem de

analiza western blott) 2008 45.993,50

Cercetare MEC

75

Sistem de electroforeza si

Western Blotting 2008 16.303,00

Cercetare MEC

76 Placa sofanta 2008 6.892,88 Cercetare MEC

77

Disp.pt.tehnica Tisuue

microassay 2008 8.496,60

Cercetare MEC

78 Detector de ozon 2008 39.680,55 Cercetare MEC

79 Procesor tesuturi 2008 124.937,92 Cercetare MEC

80 Incubator de culturi celulare 2008 17.635,80 Cercetare MEC

81

Instalatie de purificare a

aerului 2008 45.941,14

Cercetare MEC

82 Hota cu flux laminar cls. II 2008 44.510,28 Cercetare MEC

83

Placa de baza pt.fix.pacient +

accesorii 2008 21.935,27

Cercetare MEC

84 LAMPA BACTERICIDA 60 PL 2008 3.000,00 Cercetare MEC

85 Centrifuga cu racire 2008 37.213,68 Cercetare MEC

86 Procesor de tesuturi 2008 62786.32 Cercetare MEC

87 Hota de culturi cls.II 2008 7.259,00 Cercetare MEC

88 Lightcycler 2008 185.640,00 Cercetare MEC

89 Lampa scialitica cu satelit 2008 41.888,00 Cercetare MEC

90

Instalatie de purificare a

aerului pentru indepartarea

speciilor de ozon active 2008 91.882,28

Cercetare MEC

91

Upgrade Microscop Zeiss

Axio Observer 2008 99.305,50

Cercetare MEC

13

92 Pistol de prelevare biopsii 2008 9.282,00 Cercetare MEC

93 Ecograf Acuson X 300 2008 104.779,50 Cercetare MEC

94

Sistem de upgradare

centrifuga Universal 32 R 2008 3.857,98

Cercetare MEC

95 Analozor lightcycler 2008 185.640,00 Cercetare MEC

96 UV/Metru 2009 7.199,50 Cercetare MEC

97

Lampa cercetare cu

ultraviolete 2009 6.985,30

Cercetare MEC

98 Tije politron 2009 46.652,76 CNCSIS

99 UV/Metru 2009 7.199,50 Cercetare MEC

100

Lampa cercetare cu

ultraviolete 2009 6.985,30

Cercetare MEC

101

Locator 4110 litri cu sistem

de role portabile 2009 31.319,26

Cercetare MEC

102 Platforma microarray 2007 145.000 Cercetare MEC

___________ 1) Se mentioneaza forma de organizare si persoana juridica: daca unitatea de cercetare-

dezvoltare nu are personalitate juridica, se mentioneaza denumirea institutiei cu

personalitate juridica care o reprezinta (de exemplu, Centrul de ............... din cadrul

Universitatii ...............). 2) Se mentioneaza titlul actului, data emiterii, organul emitent si, dupa caz, modificarile

ulterioare

3) Domeniile de clasificare UNESCO pot fi accesate la www.mct.ro/ancs.

4) Indexate de Thomson Scientific [fost Institute for Scientific Information (ISI) in Science

Citation Index Expanded, Social Sciences Citation Index sau Arts & Humanities Citation Index].

5) Punctajul ISI se obtine prin insumarea factorilor de impact ai publicatiilor respective.

Factorii de impact pot fi accesati la www.cimec.org.ar.

6) Sunt excluse autocitarile.

14

7) Se specifica daca brevetul este national/international (USPTO, EPO, JPO) si numarul

brevetului.

8) In cazul revistelor romanesti, sunt luate in considerare cele cotate CNCSIS, categoria B (vezi

www.cncsis.ro).

9) Valori defalcate pe ani si valoarea totala in euro.

10) Datele vor fi prezentate pe tipuri de programe (PNCDI, CEEX, granturi etc.); valorile

contractelor vor fi defalcate pe ani.

Reprezentant legal

Institutul Oncologic “Prof Dr I.Chiricuta”

Manager

Conf.Dr.Alexandru Irimie

Director cercetare - dezvoltare

Sef lucrari . Dr. Ioana Neagoe

15

ANEXA 4.1

Lucrari stiintifice/tehnice publicate in reviste de specialitate cotate ISI4)

84X 30 = 2520 ;

Punctaj cumulat ISI 324.714 x 5= 1623.57 ;

Citari – 4031 X 5 = 20.155

Total= 24298.57

2005

1. I.D. Postescu, C. Tatomir, G.Chereches, I.Brie, G .Damian , D.Petrisor, A.M.Hosu,

N.Pop: Spectroscopic characterisation of grape extracts with potential role in tumor

growth inhibition, J. Optoel. Adv. Materials (JOAM), 9, 564-567, 2007 (ISI-2005,

impact factor 1.138) citari 6

2. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S,

Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay

B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P, Seymour L; National Cancer

Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-

cell lung cancer. N Engl J Med. 2005 Jul 14;353(2):123-32.PMID: 16014882 Factor de

impact 2005 - 44,016

3. Eniu A, Palmieri FM, Perez EA. Weekly administration of docetaxel and paclitaxel in

metastatic or advanced breast cancer. Oncologist. 2005 Oct;10(9):665-85.

Review.PMID: 16249346 Factor de impact 2005 3,962

4. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J,

Thongprasert S, Tan EH, Pemberton K, Archer V, Carroll K. Gefitinib plus best

supportive care in previously treated patients with refractory advanced non-small-

cell lung cancer: results from a randomised, placebo-controlled, multicentre study

16

(Iressa Survival Evaluation in Lung Cancer). Lancet. 2005 Oct 29-Nov

4;366(9496):1527-37.PMID: 16257339 Factor de impact 23,4

2006

5. - R.Cosnarovici, Şt. Neamţu, E.Mihuţ, D.Cernea, N.Todor, Luciana Neamţiu, The

benefit of high dose methotrexate terapy in childhood, Pediatric Blood & Cancer,

47,4, pp.443-444 Factor de impact 1,882

6. Veronique Winnepenninckx, Vladimir Lazar, Stefan Micheils, Philippe Dessen,

Marguerite Stas, Soledad R. Alonso, Marie-Franoise Avril, Pablo L. Ortiz Romero,

Thomas Robert, Ovidiu Balacescu, Alexander M.M. Eggremont, Gilbert Lenoir, Alain

Sarasin, Thomas Tursz, Joost J. van den Oord, Alain Spatz. On behalf of the Melanoma

Group of the European Organization for Research and Treatment of Cancer. Gene

expression profiling of primary cutaneous melanoma and clinical outcome. J Natl

Cancer Inst, 2006 apr 5, 98 (7): 472-82.factor de impact 15,271 nr de citari -106 in

sistem Google Scholar

7. Dorhoi, V. Dobrean, M. Zahan, P. Virag. Modulatory effects of several herbal

extracts on avian peripheral blood cell immune responses, Phytotherapy Research,

factor de impact 0, 508, 2006, 20(5): 352-358. John Wiley & Sons

8. Hirsch FR, Varella-Garcia M, Bunn PA Jr, Franklin WA, Dziadziuszko R, Thatcher N,

Chang A, Parikh P, Pereira JR, Ciuleanu T, von Pawel J, Watkins C, Flannery A, Ellison

G, Donald E, Knight L, Parums D, Botwood N, Holloway B. Molecular predictors of

outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-

cell lung cancer. J Clin Oncol. 2006 Nov 1;24(31):5034-42.PMID: 17075123 Factor de

impact 1.376

17

9. Eniu A, Carlson RW, Aziz Z, Bines J, Hortobágyi GN, Bese NS, Love RR, Vikram B,

Kurkure A, Anderson BO; Global Summit Treatment and Allocation of Resources

Panel. Breast cancer in limited-resource countries: treatment and allocation of

resources Breast J. 2006 Jan-Feb;12 Suppl 1:S38-53.PMID: 16430398 Factor de

impact 1,61

10. Benjamin O. Anderson, MD*, Roman Shyyan, MD † , Alexandru Eniu, MD ‡ , Robert A.

Smith, PhD § , Cheng-Har Yip, MD ¶ , Nuran Senel Bese, MD # , Louis W. C. Chow, MD ^

, Shahla Masood, MD € , Scott D. Ramsey, MD, PhD ¢ , and Robert W. Carlson, MD**

*University of Washington, Seattle, Washington; † Lviv Cancer Center, Lviv, Ukraine; ‡ Cancer Institute I. Chiricuta, Cluj-Napoca, Romania; § American Cancer Society,

Atlanta, Georgia; ¶ University of Malaya Medical Center, Kuala Lumpur, Malaysia; #

Cerrahpasa Medical School, Istanbul, Turkey; ^ University of Hong Kong Medical

Center, Pokfulam, Hong Kong; €University of Florida, Jacksonville, Florida; ¢ Fred

Hutchinson Cancer Research Center, Seattle, Washington; and **Stanford

University, Stanford, California Breast Cancer in Limited-Resource Countries: An

Overview of the Breast Health Global Initiative 2005 Guidelines The Breast Journal

2006 Volume 12 Issue s1, Pages S3 - S15 Published Online: 16 Jan 2006 Factor de

impact 1,61

11. Brodowicz T, Krzakowski M, Zwitter M, Tzekova V, Ramlau R, Ghilezan N, Ciuleanu T,

Cucevic B, Gyurkovits K, Ulsperger E, Jassem J, Grgic M, Saip P, Szilasi M, Wiltschke C,

Wagnerova M, Oskina N, Soldatenkova V, Zielinski C, Wenczl M; Central European

Cooperative Oncology Group CECOG. Cisplatin and gemcitabine first-line

chemotherapy followed by maintenance gemcitabine or best supportive care in

advanced non-small cell lung cancer: a phase III trial. Lung Cancer. 2006

May;52(2):155-63. Epub 2006 Mar 29.PMID: 16569462 Factor de impact 3.554

18

12. Cucuianu A, Patiu M, Rusu A. Hepcidin and multiple myeloma related anemia.

Medical Hypotheses, ISSN 0306-9877, 66:352-354, 2006 – idexat ISI – IF=1.393

2007

13. Daria Cosaceanu, Mia Carapancea, Oana Alexandru, Raluca Budiu, Hanna-

Stianmartinsson, Maria Starborg, Maria Vrabete, Lena Kanter, Rolf Lewensohn, Anica

Dricu. Comparison of three approaches for inhibiting insulin-like growth factor I

receptor and their effects on NSCLC cell lines in vitro. Growth Factors; 2007, 25 (1): 1-

8. factor de impact – 3,95

14. D Cosaceanu, RA Budiu, M Carapaceanu, J Castro, R Lewensohn, A Dricu. Ionizing

radiation activates IGF-1R triggering a cytoprotective signaling by interfering with Ku-

DNA binding modulating Ku86 expression via p38 kinase-dependent mechanism.

Oncogene, 2007. 26, 2423-2434 factor de impact- 6,582

15. Carapancea M, Cosaceanu D, Budiu R, Kwiecinska A, Tataranu L, Ciubotaru V,

Alexandru O, Banita M, Pisoschi C, Backlund ML, Lewensohn R, Dricu A. Dual

targeting of IGF-1R and PDGFR inhibits proliferation in high-grade gliomas cells and

induces radiosensitivity in JNK-1 expressing cells. Neurooncol. 2007 Dec;85(3):245-

54. Epub 2007 Jun 14 factor de impact – 1,84

16. Radulescu D, Pripon S, Ciuleanu TE, Radulescu LI. Malignant primary pulmonary

tumor with hemangiopericytoma-like features: conventional hemangiopericytoma

versus solitary fibrous tumor. Clin Lung Cancer. 2007 Sep;8(8):504-8.PMID: 17922977

Factor de impact - 2,39

19

17. Radulescu D, Pripon S, Parv A, Duncea C, Ciuleanu TE. Altered left ventricular

diastolic performance in oncologic patients treated with epirubicin.Congest Heart

Fail. 2007 Jul-Aug;13(4):215-20.PMID: 17673874 Factor de impact 2007 – 3,6

18. Grigorescu A, Ciuleanu T, Firoiu E, Muresan DR, Teodorescu G, Basson BR. A

randomized phase II trial of sequential gemcitabine plus vinorelbine followed by

gemcitabine plus ifosfamide versus gemcitabine plus cisplatin in the treatment of

chemo-naive patients with stages III and IV non-small cell lung cancer (NSCLC). Lung

Cancer. 2007 Aug;57(2):168-74. Epub 2007 Apr 30.PMID: 17467848 Factor de impact

2007 – 3,455

19. I.D. Postescu, C. Tatomir, G. Cherecheş, I. Brie, G. Damian, D. Petrişor, A-M Hosu, V.

Miclăuş, A. Pop: Spectroscopic characterization of some grape extracts with potential

role in tumor growth inhibition, Journal of Optoelectronics and Advanced Materials,

2007, 9(3), 564-567, Factor de impact 0.577.

2008

20. Langer CJ, O'Byrne KJ, Socinski MA, Mikhailov SM, Leśniewski-Kmak K, Smakal M,

Ciuleanu TE, Orlov SV, Dediu M, Heigener D, Eisenfeld AJ, Sandalic L, Oldham FB,

Singer JW, Ross HJ. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in

combination with carboplatin versus standard paclitaxel and carboplatin in the

treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung

cancer. J Thorac Oncol. 2008 Jun;3(6):623-30.PMID: 18520802 [PubMed - indexed for

MEDLINE]Related citations Factor de impact 2008 – 4,547

21. Smith RE Jr, Aapro MS, Ludwig H, Pintér T, Smakal M, Ciuleanu TE, Chen L, Lillie T,

Glaspy JA. Darbepoetin alpha for the treatment of anemia in patients with active

cancer not receiving chemotherapy or radiotherapy: results of a phase III,

multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol. 2008

20

Mar 1;26(7):1040-50. Epub 2008 Jan 28.PMID: 18227526 Factor de impact 2006 -

13.598

22. Eniu A, Carlson RW, El Saghir NS, Bines J, Bese NS, Vorobiof D, Masetti R, Anderson

BO; Breast Health Global Initiative Treatment Panel. Guideline implementation for

breast healthcare in low- and middle-income countries: treatment resource

allocation. Cancer. 2008 Oct 15;113(8 Suppl):2269-81.PMID: 18837019 Factor de

impact 5,418

23. El Saghir NS, Eniu A, Carlson RW, Aziz Z, Vorobiof D, Hortobagyi GN; Breast Health

Global Initiative Systemic Therapy Focus Group. Locally advanced breast cancer:

treatment guideline implementation with particular attention to low- and middle-

income countries. Cancer. 2008 Oct 15;113(8 Suppl):2315-24.PMID: 18837023 Factor

de impact 5,418

24. Masood S, Vass L, Ibarra JA Jr, Ljung BM, Stalsberg H, Eniu A, Carlson RW, Anderson

BO; Breast Health Global Initiative Pathology Focus Group. Breast pathology

guideline implementation in low- and middle-income countries. Cancer. 2008 Oct

15;113(8 Suppl):2297-304.PMID: 18837021 Factor de impact 5,418

25. Bines J, Eniu A. Effective but cost-prohibitive drugs in breast cancer treatment: a

clinician's perspective. Cancer. 2008 Oct 15;113(8 Suppl):2353-8. Review.PMID:

18837028 Factor de impact 5,418

26. Dima D, Trifa AP, Cucuianu A, Popp RA, Patiu M, Petrov L. Monitoring T315I mutation

in chronic myeloid leukemia by amplification refractory mutation system PCR. Rom

Rev Lab Med. 2008, 13,4:17-20 – indexat ISI - IF=0

21

27. Patiu M., Laszlo G., Cucuianu A.: Feritins in iron metabolism investigation. Revista

Romana de Medicina de Laborator.vol 11 nr 2 iunie 2008 pag 53-55 indexat ISI – IF = 0

28. S.Suciu, I.D. Postescu, A. Mureşan, P. Virág, D. Daicoviciu, E. Fischer-Fodor. In vitro

and in vivo Studies on the Modulatory Effects of a Grape (Vitis vinifera) Seed Extract,

J. Clin. Biochem. Nutr., 2008, Suppl. 43, 493-96, i.f. 0.312.

29. E.Fischer-Fodor, N. Moldovan, P. Virág, O. Soriţău, I. Brie, P. Lonnecke, E. Hey-

Hawkins, L. Silaghi Dumitrescu: The CellScan Technology for In Vitro Studies on Novel

Platinum Complexes with Organoarsenic Ligands, Dalton Transactions, 2008, 6393-

6400, i.f. 3.58.

30. T.Dicu, I. Brie, P. Virág, E. Fischer, M. Perde, V. Foriş, V. Cernea, C. Cosma.

Genotoxic effects of 60Co γ-rays on Chinese hamster ovary (CHO) cells, Nukleonika,

2008, 53 (4), 161-165, i.f. 0.267.

31. A.Filip, S. Clichici, A. Mureşan, D. Daicoviciu, C. Tatomir, C. Login, S. Dreve, C.

Gherman: Effects of PDT with 5-aminolevulinic acid and chitosan on Walker

Carcinosarcoma. Exp. Oncol., 2008, 30, 3, 212-219, i.f. 0.115.

2009

32. Ciuleanu T, Brodowicz T, Zielinski C, Kim JH, Krzakowski M, Laack E, Wu YL, Bover I,

Begbie S, Tzekova V, Cucevic B, Pereira JR, Yang SH, Madhavan J, Sugarman KP,

Peterson P, John WJ, Krejcy K, Belani CP. Maintenance pemetrexed plus best

supportive care versus placebo plus best supportive care for non-small-cell lung

22

cancer: a randomised, double-blind, phase 3 study. Lancet. 2009 Oct

24;374(9699):1432-40. Epub 2009 Sep 18.PMID: 19767093 Factor de impact 30,758

33. Socinski MA, Smit EF, Lorigan P, Konduri K, Reck M, Szczesna A, Blakely J,

Serwatowski P, Karaseva NA, Ciuleanu T, Jassem J, Dediu M, Hong S, Visseren-Grul C,

Hanauske AR, Obasaju CK, Guba SC, Thatcher N. Phase III study of pemetrexed plus

carboplatin compared with etoposide plus carboplatin in chemotherapy-naive

patients with extensive-stage small-cell lung cancer. J Clin Oncol. 2009 Oct

1;27(28):4787-92. Epub 2009 Aug 31.PMID: 19720897Factor de impact 13.598

34. Gatzemeier U, Ciuleanu T, Dediu M, Ganea-Motan E, Lubenau H, Del Giglio A. XM02,

the first biosimilar G-CSF, is safe and effective in reducing the duration of severe

neutropenia and incidence of febrile neutropenia in patients with small cell or non-

small cell lung cancer receiving platinum-based chemotherapy. J Thorac Oncol. 2009

Jun;4(6):736-40.PMID: 19404210 Factor de impact 4,547

35. Le Péchoux C, Dunant A, Senan S, Wolfson A, Quoix E, Faivre-Finn C, Ciuleanu T,

Arriagada R, Jones R, Wanders R, Lerouge D, Laplanche A; Prophylactic Cranial

Irradiation (PCI) Collaborative Group. Standard-dose versus higher-dose prophylactic

cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in

complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01,

EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial. Lancet

Oncol. 2009 May;10(5):467-74. Epub 2009 Apr 20.PMID: 19386548 Factor de impact

10.119

36. Ciuleanu TE, Pavlovsky AV, Bodoky G, Garin AM, Langmuir VK, Kroll S, Tidmarsh GT. A

randomised Phase III trial of glufosfamide compared with best supportive care in

metastatic pancreatic adenocarcinoma previously treated with gemcitabine. Eur J

23

Cancer. 2009 Jun;45(9):1589-96. Epub 2009 Jan 31.PMID: 19188061 Factor de

impact 4.167

37. O Tudoran. I Berindan Neagoe, O Balacescu, E Dronca, C. Burz, L Balacescu, I

Nedelea, Al. Irimie, O. Popescu, Al Irimie, V. Cristea. Evaluation of tumor

angiogenesis through VEGF modulkation in ovarian cancer in vitro using RNA

interference. Romanian Biotechnological Letters, 2009 vol 14, no.4, 4560-4566. ISI

factor impact 0.152

38. Burz C, Berindan-Neagoe IB, Balacescu O, Tanaselia C, Ursu M, Gog A, Vlase L,

Chintoanu M, Balacescu L, Leucuta SE, Irimie A, Cristea V. Clinical and

pharmacokinetics study of oxaliplatin in colon cancer patients. J Gastrointestin Liver

Dis. 2009 Mar;18(1):39-43. 1 citare in Google Scholar. FI=1.265

39. Burz C, Berindan-Neagoe I, Balacescu O, Irimie A. Apoptosis in cancer: Key

molecular signaling pathways and therapy targets. Acta Oncol. 2009 Jun 9:1-11. ISI,

Factor de impact (2008): 2.739 nr de citari -8 in sistem Google Scholar.

40. Vlad AM, Budiu RA, Lenzner DE, Wang Y, Thaller JA, Colonello K, Crowley-Nowick PA,

Kelley JL, Price FV, Edwards RP. A phase II trial of intraperitoneal interleukin-2 in

patients with platinum-resistant or platinum-refractory ovarian cancer. Cancer

Immunol Immunother. 2009 Aug 19. [Epub ahead of print]. ISI, Factor de impact

(2009): 3.791

41. Budiu RA, Diaconu I, Chrissluis R, Dricu A, Edwards RP, Vlad AM. Dis Model Mech. A

conditional mouse model for human MUC1-positive endometriosis shows the

presence of anti-MUC1 antibodies and Foxp3+ regulatory T cells. Dis Model Mech.

24

2009 Nov-Dec;2(11-12):593-603. Epub 2009 Oct 19. ISI, Factor de impact (2009):

3.304

42. Nicula FA. Suteu O. Pais R. Neamtiu L. Description of the national situation of

cervical cancer screening in the member states of the European Union. Eur J Cancer

2009;45:2685-2708. Factor de impact 4,121

43. Ronco G. Balegooijen M. Becker N. Chil A. Fender M. Giubilato P. Kurtinaitis J.

Lancucki L. Lynge E. Morais A. O’Reilly M. Sparen P. Suteu O. Rebolj M. Veerus P.

Primic Zakelj M. Anttila A. Process performance of cervical screenning programmes in

Europe. Eur J. Cancer, 2009;45:2659-2670. Factor de impact 4,121

44. Anttila A. Von Karsa L. Aasmaa A. Fender M. Patnick J. Rebolj M. Nicula F. Vass

L.Valerianova Z. Voti L. Sauvaget C. Ronco G. Cervical cancer screening policies and

coverage in Europe. Eur J Cancer 2009; 45:2649-2658. Factor de impact 4,121

45. Nicula F. A. Anttila A. Neamtiu L. Primic Zachelj M. Tachezy R. Chill A. Grce M. Kesic

V. Challenges in starting organised screening programmes for cervical cancer in the

new member states of the European Union. Eur J Cancer 2009; 45: 2679-2684.

Factor de impact 4,121

46. Neamţiu L. A Medical Resources Allocation Problem. Results in Mathematics.

Birkhauser Verlag Basel/ Swizerland, 53(2009), p. 341-348. Factor de impact 0,513

47. Buzas C, Sparchez Z, Cucuianu A, Manole S, Lupescu I, Acalovschi M. Budd-Chiari

syndrome secondary to polycythemia vera. A case report. J Gastrointest Liver Dis,

2009, 18(3):363-6 – indexat ISI – IF=1.265

25

48. Trifa AP, Popp RA, Cucuianu A, Dima D, Militaru MS, Patiu M, Pop IV. JAK2 p.V617F

mutation - tetra-primer PCR and PCR-RFLP comparative semiquantitative approaches

for estimation of the mutant allele in myeloproliferative neoplasms. Rom Rev Lab

Med. 2009, 14,1:23-36 – indexat ISI – IF=0

49. P.Virág, I. Brie, I.D. Postescu, M. Perde-Schrepler, E. Fischer-Fodor, O. Soriţău, A.

Irimie, V. Cernea. Comparative study of two evaluation methods for the genotoxic

effects of environmental heavy metals on normal cells, Toxicol. Ind. Health, 25 (4-5),

2009, 253-8, i.f. 0.700.

50. A. Filip, S. Clichici, D. Daicoviciu, A.Mureşan, I. D. Postescu, M. Perde- Schrepler, D.

Olteanu: Photochemoprevention of cutaneous neoplasia through natural products,

Exp. Oncol., ISSN 0204-3564, 2009 Mar; 31(1), 9-15, i.f. 0.115.

51. T. Dicu, I. D. Postescu, V. Foriş, I. Brie, E. Fischer-Fodor, M. Moldovan, C. Cosma:

The effect of a grape seed extract on radiation-induced DNA damage in human

lymphocytes, Amer. Inst. Phys. Conf. Proceed., 2009, 1131, 181-187.

52. M. C. Mihu, D. Rus Ciucă, O. Soriţău, S. Susman, D. Mihu: Isolation and

characterization of mezenchymal stem cells from the amniotic membrane, Romanian

Journal of Morphology and Embryology, 2009; 50(1):73-77.

53. M. Lukáč, M. Mrva, E. Fischer-Fodor, I. Lacko, M. Bukovský, N. Miklášová, F.

Ondriska, F. Devínsky : Synthesis and biological activity of dialkylphosphocholines

Elsevier, Bioorganic & Medicinal Chemistry Letters 19, 2009, 6346-6349, i.f. 2.531.

54. N. Miklášová, E. Fischer-Fodor, P. Lonnecke, M. Perde Schrepler, P. Virág, C.

Tatomir, V. I. Cernea, E. Hey-Hawkins, L. Silaghi- Dumitrescu: Antiproliferative effect

26

and genotoxicity of novel synthesized palladium complexes with organoarsenic

ligands, J. Inorg. Biochem., 2009, 103, 1739-1747, i.f. 3.133.

55. C. Tomuleasa, S. Şuşman, O. Soriţău, V. Foriş, E. Páll, C. Mihu: Primum non nocere.

Is stem cell research ready for clinical trials?, Journal of Euroepan Medical Students’

Association on Medical and Scientific Affairs JEMSA, 2009, 34-38.

56. C. Tomuleasa, V. Foris, O. Soriţău, E. Páll, E. Fischer-Fodor, V. Lung-Illes, I. Brie,

P.Virág, M. Perde-Schrepler, I. D. Postescu, G. Cherecheş, O. Bărbos, C. Tatomir.

Effects of 60Co gamma-rays on human osteoprogenitor cells.Rom J Morphol

Embryol 2009; 50(3):349-55.

57. O. Lucaciu, M. Băciuţ, G. Băciuţ, D. Gheban, S. Bran, M. Hedeşiu, C. Nicola, O.

Soriţău, D. Gui: Bone Regeneration in Craniofacial Reconstruction with Particulate

Grafts Obtained Through Tissue Engineering. Particulate Science and Technology An

International Journal, 2009 ; 27, 6 , 497–518, ISSN- 0272-6351, i.f. 0.417.

58. A. Mureşan, Ş. Suciu, S. Ghibu, D. Daicoviciu, I. D. Postescu, I. Login: Antioxidant

effects of polyphenols in experimental hypobaric hypoxia, Bull. USAMV, 2009, 66(1),

160-164 (revistă ISI din 2009). ISSN-1454-2382.

59. Seicean A, Popa D, Mocan T, Cristea V, Neagoe I. Th1 and Th2 profiles in patients

with pancreatic cancer compared with chronic pancreatitis. Pancreas. 2009

Jul;38(5):594-5.Factor de impact 2,733

60. I. Berindan Neagoe, O. Balacescu, C. Burz, C. Braicu, L. Balacescu, O. Tudoran,

T.Kaucsar, V.Cristea, A. Irimie. p53 gene therapy using RNA interference. Journal of

B.U.O.N.14,SEPT 2009, S 51-S 59 Factor de Impact 0.783

27

2010-

61. Cappuzzo F, Ciuleanu T, Stelmakh L, Cicenas S, Szczésna A, Juhász E, Esteban E,

Molinier O, Brugger W, Melezínek I, Klingelschmitt G, Klughammer B, Giaccone G;

SATURN investigators. Erlotinib as maintenance treatment in advanced non-small-

cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

Lancet Oncol. 2010 Jun;11(6):521-9. Epub 2010 May 20.PMID: 20493771 Factor de

impact 10.119

62. Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV,

Dudnichenko AS, Aleknaviciene B, Razbadauskas A, Gore M, Ganea-Motan E,

Ciuleanu T, Wimberger P, Schmittel A, Schmalfeldt B, Burges A, Bokemeyer C,

Lindhofer H, Lahr A, Parsons SL. The trifunctional antibody catumaxomab for the

treatment of malignant ascites due to epithelial cancer: Results of a prospective

randomized phase II/III trial. Int J Cancer. 2010 Apr 27. [Epub ahead of print]PMID:

20473913 Factor de impact 4.693

63. Steger GG, Abrahámová J, Bacanu F, Brincat S, Brize A, Cesas A, Cufer T, Dank M,

Duchnowska R, Eniu A, Jassem J, Kahán Z, Matos E, Padrik P, Plāte S, Pokker H,

Purkalne G, Timcheva C, Tzekova V, Vyzula R, Zielinski CC. Current standards in the

treatment of metastatic breast cancer with focus on Lapatinib: a review by a Central

European Consensus Panel. Wien Klin Wochenschr. 2010 Jun;122(11-12):368-79.

Epub 2010 Jun 15.PMID: 20549373 Factor de impact 0.804

64. Cornelia Braicu, Dumitrita Rugina, Veronica Sanda Chedea, Oana Tudoran, Ovidiu

Balacescu, Ioana Neagoe And Carmen Socaciu, Protective action of different natural

flavan-3-ols against aflatoxin B1-related cytotoxicity, Journal of Food Biochemistry,

Volume 34 Issue 3, Pages 595 – 610, Published Online: 3 Mar 2010; ISI, Factor de

impact (2009)=0.779; nr de citari -1 in sistem Google Scholar.

28

65. Achimaş-Cadariu P, Irimie A, Achimaş-Cadariu L, Neagoe I, Buiga R. Chirurgia (Bucur).

2009 May-Jun;104(3):287-93. ISI

66. Cornelia Braicu, Ioana Berindan-Neagoe, Veronica Sanda Chedea, Loredana

Balacescu, Ioana Brie, Olga Soritau, Carmen Socaciu, Alexandru Irimie. Individual

and combined cytotoxic effects of the major four aflatoxins in different in vitro

stabilized systems, Journal of Food Biochemistry Published Online: Mar 3 2010

4:34AM, DOI: 10.1111/j.1745-4514.2010.00350.x ISI, Factor de impact (2009)=0.77.

67. Veronica Sanda Chedea, Cornelia Braicu, Carmen Socaciu, Antioxidant/prooxidant

activity of a polyphenolic grape seed extract, Food Chemistry , Volume 121, Issue 1,

Published Online: 1 July 2010, Pages 132-139, doi:10.1016/j.foodchem.2009.12.020

ISI Factor de impact (2009)= 3.146

68. Rantakari P, Nikkilä J, Jokela H, Ola R, Pylkäs K Lagerbohm H, Sainio K, Poutanen M,

Winqvist R. Inactivation of Palb2 gene leads to mesoderm differentiation defect and

early embryonic lethality in mice. Hum Mol Genet. 2010 Aug 1;19(15):3021-9. Epub

2010 May 18. ISI, Factor de impact (2010):7.386

69. Jokela H, Rantakari P, Lamminen T, Strauss L, Ola R, Mutka AL, Gylling H, Miettinen T,

Pakarinen P, Sainio K, Poutanen M. Hydroxysteroid (17beta) dehydrogenase 7

activity is essential for fetal de novo cholesterol synthesis and for neuroectodermal

survival and cardiovascular differentiation in early mouse embryos. Endocrinology.

2010 Apr;151(4):1884-92. Epub 2010 Feb 25. ISI, Factor de impact (2009):5.257

70. Jääskeläinen M, Prunskaite-Hyyryläinen R, Naillat F, Parviainen H, Anttonen M,

Heikinheimo M, Liakka A, Ola R, Vainio S, Vaskivuo TE, Tapanainen JS. Mol Cell

29

Endocrinol. 2010 Apr 12;317(1-2):106-11. Epub 2009 Dec 3. WNT4 is expressed in

human fetal and adult ovaries and its signaling contributes to ovarian cell survival.

Mol Cell Endocrinol. 2010 Apr 12;317(1-2):106-11. Epub 2009 Dec 3. ISI, Factor de

impact (2009): 3.503

71. Trifa AP, Cucuianu A, Petrov L, Urian L, Militaru S, Dima D, Pop IV, Popp RA.The G

allele of the JAK2 rs10974944 SNP, part of JAK2 46/1 haplotype, is strongly

associated with JAK2 V617F-positive myeloproliferative neoplasms. Ann. Hematol

2010 Apr 27 (epub ahead of print) – indexat ISI – IF=2.919

72. Trifa AP, Cucuianu A, Popp RA. Development of a reliable PCR-RFLP assay for

investigation of the JAK2 rs10974944 SNP, which might predispose to the

acquisition of somatic mutation JAK2(V617F). Acta Haematol. 2010;123(2):84-7 –

indexat ISI – IF=1.069

73. Cucuianu A, Precup R. A hypothetical-mathematical model of acute myeloid

leukaemia pathogenesis. Computational and Mathematical Methods in Medicine,

2010, 11 (1):49 – 65 – indexat ISI – IF=0

74. I. D. Postescu, P. Virág, M. Achim, E. Fischer-Fodor: Influence of palm oil on

doxorubicine induced cytotoxicity in normal and tumor cell cultures, Phytoter. Res.

2010, 24, 154-156, i.f. 1.772.

75. L. I. Sabău, G. Damian, D. Daicoviciu, A. Mureăan, I. D. Postescu, D. Mihu, C. Mihu,

N. Costin, C. Alb: In vivo study regarding antioxidant effect of red grape polyphenol

extract using biochemical and FT-IR methods, J.Optoel.Adv.Mater. (JOAM), 2(1),

2010, 44-49, i.f. 0.577.

30

76. T. Dicu, I. D. Postescu, C. Tatomir, M. Tămaş, C. Cosma: A method to measure the

antioxidant properties of polyphenolic compounds in trapping DPPH radical, under

review at Ital.J.Food Sci, 2010, i.f. 0.462.

77. I. D. Postescu, P. Virág, T. Dicu, C. Tatomir, E. Fischer-Fodor, I. Brie, M. Perde-

Schrepler, I. V. Cernea: The cyto- and radioprotective effects of a whey protein

isolate, under review at Dairy Sci. Technol, 2010, i.f. 1.012.

78. C. Tomuleasa, O. Soriţãu, I. Brie, E. Páll, V. Foris, T. Dicu, P. Virag, A. Irimie, G.

Kacsó: Mesenchymal stem cell irradiation in culture engages differential effect of

hyperfractionated radiotherapy for head and neck cancers, Journal of Balkanic

Union of Oncology, 15:348-356, 2010.Factor de Impact 0.783

79. C. Tomuleasa, O. Soriţău, D. Rus-Ciucă, T. Pop, D. Todea, O. Mosteanu, B. Pintea, V.

Foris, S. Şuşman, G. Kacsó, A. Irimie: Isolation and Characterization of Hepatic

Cancer Cells with Stem-like Properties from Hepatocellular Carcinoma, J

Gastrointestinal Liver Dis, 19, 1, 2010, 61-67, i.f. 1.265.

80. O. Soritau, C. I. Tomuleasa, E. Pall, P. Virag, E. Fischer-Fodor, V. Foris, O. Barbos, C.

Tatomir, G. Kacso, A. Irimie: Enhanced chemoresistance and tumor sphere formation

as a laboratory model for peritoneal micrometastasis in epithelial ovarian cancer,

Romanian Journal of Morphology and Embryology, 2010, 51 (2): 259-64.

81. C. Tomuleasa, G. Kacso, O. Soritau, S. Susman, A. Irimie, P. Virag: Cellular

interactions in prostate cancer genesis and dissemination. Looking beyond the

obvious, Romanian Journal of Morphology and Embryology, 2010, 51 (3): 3-6.

82. C.G. Precup, D. Gonganau-Nitu, R.R. Scurtu, G. Dindelegan, A. Biro, O. Soritau, C.

Crişan, O. Serban, G. Pufu, C. Ciuce.: Assessement by laser Doppler of the peripheral

31

tumour perfusion after radiofrequency ablation for colorectal liver mestasis-

experimental study. Chirurgia (Bucur). 2010 Jan-Feb;105(1):71-6.

83. O. Lucaciu, M. Băciuţ, G. Băciuţ, R. Câmpian, O. Soriţău, S. Bran, B. Crişan, L.

Crişan.: Tissue engineered bone versus alloplastic commercial biomaterials in

craniofacial reconstruction. Rom J Morphol Embryol. 2010;51(1):129-36.

84. S.Clichici, A.Filip, D. Daicoviciu, R.M. Ion, T. Mocan, C.Tatomir, L.Rogojan,

D.Olteanu, A. Muresan: The dynamics of reactive oxygen speciesin photodynamic

therapywith tetra sulfophenil- porphyrin. Acta Physiologica Hungarica, vol 97 (1), 43-

55, 2010. ISSN 0231-424X (ISI), i.f. 0.491.

32

Citari ISI

1. Erlotinib in previously treated non-small-cell lung cancer

nejm.org [HTML]… Rodrigues Pereira, T Ciuleanu, EH Tan, V … - … England Journal of …,

2005 - content.nejm.org. Results The median age of the 731 patients who underwent

randomization was 61.4 years; 49 percent had received two prior chemotherapy

regimens, and 93 percent had received

platinum-based chemotherapy. The response rate was 8.9 percent in the erlotinib group

...

Citat de 2032 ori - Articole cu conţinut similar - Toate cele 17 versiuni

2. Gefitinib plus best supportive care in previously treated patients with refractory

advanced non-small-cell lung cancer: results from a randomised, placebo-controlled,

…pharmacist.or.kr [PDF]… P Parikh, J Rodrigues Pereira, T Ciuleanu, J von Pawel … - The

Lancet, 2005 - Elsevier

1129 patients were assigned gefitinib and 563 placebo. At median follow-up of 7·2

months, median survival did not differ significantly between the groups in the overall

population (5·6 months for

gefitinib and 5·1 months for placebo; hazard ratio 0·89 [95% CI 0·77–1·02], p=0·087) or

...


3. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in

advanced non-small-cell lung cancer\ascopubs.org [HTML]… , JR Pereira, T Ciuleanu, J

von Pawel, C … - Journal of Clinical …, 2006 - jco.ascopubs.org

Results High EGFR gene copy number was a predictor of a gefitinib-related effect on

33

survival

(hazard ratio [HR], 0.61 for high copy number and HR, 1.16 for low copy number;

comparison

of high v low copy number HR, P = .045). EGFR protein expression was also related to ...


4. Cisplatin and gemcitabine first-line chemotherapy followed by maintenance gemcitabine

or best supportive care in advanced non-small cell lung cancer: A phase III …… , R

Ramlau, N Ghilezan, T Ciuleanu, B Cucevic, K … - Lung Cancer, 2006 - Elsevier

Between November 1999 and November 2002, we enrolled 352 patients (median age:

57 years; stage IV disease: 74%; Karnofsky performance status (KPS) >80: 41%).

Following initial therapy, 206 patients were randomized and treated with gemcitabine

(138) or best ...


5. Phase III trial comparing supportive care alone with supportive care with oral topotecan

in patients with relapsed small-cell lung cancer ascopubs.org [HTML]MER O'Brien, TE

Ciuleanu, H Tsekov, Y … - Journal of Clinical …, 2006 - jco.ascopubs.org

RESULTS: In the intent-to-treat population, survival (primary end point) was prolonged in

the topotecan group (log-rank P = .0104). Median survival with BSC was 13.9 weeks (95%

CI, 11.1 to 18.6) and with topotecan, 25.9 weeks (95% CI,18.3 to 31.6). Statistical

significance for ...


6. D Cosaceanu, RA Budiu, M Carapancea, J Castro, R … - Oncogene, 2006 - nature.com

Ionizing radiation exposure results in the activation of several tyrosine kinase receptors

that participate in radiation-induced DNA damage response and radioresistance. We

34

previously showed that insulin-like growth factor 1 receptor (IGF-1R) inhibition

enhanced radiosensitivity of non- ...

Cited by 21 - Related articles - BL Direct - All 5 versions

7. Darbepoetin alfa for the treatment of anemia in patients with active cancer not receiving

chemotherapy or radiotherapy: Results of a phase III, multicenter, randomized,

…ascopubs.org [PDF]…

Pinter, M Smakal, TE Ciuleanu, L Chen, T … - Journal of Clinical …, 2008 -

jco.ascopubs.orgRobert E. Smith Jr, Matti S. Aapro, Heinz Ludwig, Tamás Pintér, Martin

Šmakal, Tudor E. Ciuleanu, Li Chen, Tom Lillie, and John A. Glaspy From the South

Carolina Oncology Associates, Columbia, SC; Amgen Inc, Thousand Oaks; University of

California, Los ...


8. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive

care for non-small-cell lung cancer: a randomised, double-blind, phase 3

…oncobaleares.es [PDF]

T Ciuleanu, T Brodowicz, C Zielinski, JH Kim, M … - The Lancet, 2009 - ElsevierThis

randomised double-blind study was undertaken in 83 centres in 20 countries. 663

patients with stage IIIB or IV disease who had not progressed on four cycles of platinum-

based chemotherapy

were randomly assigned (2:1 ratio) to receive pemetrexed (500 mg/m 2 , day 1) plus best

...


9. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive

care for non-small-cell lung cancer: a randomised, double-blind, phase 3

35

…oncobaleares.es [PDF]T Ciuleanu, T Brodowicz, C Zielinski, JH Kim, M … - The Lancet,

2009 - Elsevier

This randomised double-blind study was undertaken in 83 centres in 20 countries. 663

patients

with stage IIIB or IV disease who had not progressed on four cycles of platinum-based

chemotherapy

were randomly assigned (2:1 ratio) to receive pemetrexed (500 mg/m 2 , day 1) plus best

...

Cited by 62 - Related articles - All 14 versions

10. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with

limited-stage small-cell lung cancer in complete remission after … maastro.nl [PDF]… ,

E Quoix, C Faivre-Finn, T Ciuleanu, R Arriagada, R … - Lancet Oncol, 2009 -

maastro.nlStandard-dose versus higher-dose prophylactic cranial ... RTOG 0212, and IFCT

99-01): a randomised

clinical trial ... Cécile Le Péchoux, Ariane Dunant, Suresh Senan, Aaron Wolfson, Elisabeth

Quoix, Corinne Faivre-Finn, Tudor Ciuleanu, Rodrigo Arriagada, Richard Jones, Rinus ...

Citat de 12 ori - Articole cu conţinut similar - Afişare ca HTML - Toate cele 13 versiuni

12. SATURN: A double-blind, randomized, phase III study of maintenance erlotinib versus

placebo following nonprogression with first-line platinum-based chemotherapy …

F Cappuzzo, T Ciuleanu, L Stelmakh, S … - ASCO Meeting …, 2009 - meeting.ascopubs.org

Background: Erlotinib (E), a small-molecule EGFR TKI, is proven to extend survival versus

placebo

(P) in 2nd/3rd-line advanced NSCLC. The phase III SATURN study (BO18192) was initiated

to evaluate E as maintenance therapy after standard 1st-line platinum-based ...

Cited by 53 - Related articles

11. A phase II trial of intraperitoneal interleukin-2 in patients with platinum-resistant or

platinum-refractory ovarian cancer AM Vlad, RA Budiu, DE Lenzner, Y Wang, JA … -

36

Cancer Immunology, …, 2010 - SpringerCancer Immunol Immunother (2010) 59:293–301

DOI 10.1007/s00262-009-0750-3 ... A phase

II trial of intraperitoneal interleukin-2 in patients ... Anda M. Vlad · Raluca A. Budiu ·

Diana E. Lenzner · Yun Wang · Julia A. Thaller · Kelly Colonello · Peggy A. Crowley-Nowick

· ...


12. Phase III trial comparing paclitaxel poliglumex (CT-2103, PPX) in combination with

carboplatin versus standard paclitaxel and carboplatin in the treatment of PS 2 … M

Smakal, TE Ciuleanu, SV Orlov, M … - Journal of Thoracic …, 2008 -

journals.lww.comCorey J. Langer, MD, FACP,* Kenneth J. O'Byrne, MD,† Mark A.

Socinski, MD,‡ Sergei M.

Mikhailov, MD,§ Krzysztof Lesniewski-Kmak, MD, Martin Smakal, MD,¶ Tudor E.

Ciuleanu, MD,#

Sergey V. Orlov, MD,** Mircea Dediu, MD, PhD,# David Heigener, MD,†† Amy J.

Eisenfeld ...


13. [CITATION] Results from a phase III, randomized, double-blind, placebo-controlled study

of darbepoetin alfa for the treatment of anemia in patients not receiving M Aapro, H

Ludwig, T Pinter, M Smakal, T Ciuleanu, L … - CA: American Association …, 2007


14. [CITATION] Molecular analysis of EGFR gene copy number, EGFR expression, and Akt

activation status in advanced non-small cell lung cancer (aNSCLC) treated A Chang, P

Parikh, JR Pereira, T Ciuleanu, J Pawel, B … - Clin Cancer Res, 2005


15. [CITATION] Survival benefit of oral topotecan plus supportive care versus supportive

care alone in relapsed, resistant SCLC MO'Brien, T Ciuleanu, H Tsekov, Y Shparyk, B

37

Čučević, … - Lung Cancer, 2005


16. Phase II open label randomized study of trabectedin (T) given as two different dosing

schedules in women with platinum-sensitive, recurrent ovarian carcinoma: A Roszak, T

Ciuleanu, M Bidzinski, T … - ASCO Meeting …, 2006 - meeting.ascopubs.org

schedules in women with platinum-sensitive, recurrent ovarian carcinoma: Preliminary

results. J. Del Campo, A. Roszak, T. Ciuleanu, M. Bidzinski, T. Hogberg, M. Wojtukienicz,

K. Boman, A. Poveda, A. Westermann and M. Izquierdo ...


17. [CITATION] A randomized placebo-controlled trial of erlotinib in patients with advanced

non-small cell lung cancer (NSCLC) following failure of 1st line or 2nd line FA Shepherd, J

Pereira, TE Ciuleanu, S Hirsh - J Clin Oncol, 2004


18. PDF] Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients

with limited-stage small-cell lung cancer in complete remission after …

maastro.nl [PDF]… , E Quoix, C Faivre-Finn, T Ciuleanu, R Arriagada, R … - Lancet Oncol,

2009 - maastro.nl

Standard-dose versus higher-dose prophylactic cranial ... RTOG 0212, and IFCT 99-01): a

randomised clinical trial ... Cécile Le Péchoux, Ariane Dunant, Suresh Senan, Aaron

Wolfson, Elisabeth

Quoix, Corinne Faivre-Finn, Tudor Ciuleanu, Rodrigo Arriagada, Richard Jones, Rinus ...

Cited by 12 - Related articles - View as HTML - All 13 versions

19. [PDF] Efficacy and safety of AZD6244 (ARRY-142886) as second-or third-line treatment of

patients with advanced non-small cell lung cancer arraybiopharma.com [PDF]… , C

Cebotaru, T Ciuleanu, D Damjanov, H … - ASCO Annual …, 2008 - arraybiopharma.com

EFFICACY AND SAFETY OF AZD6244 (ARRY-142886) AS SECOND- OR THIRD-LINE

TREATMENT

OF ... PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER ... V. Tzekova1, C.

38

Cebotaru2, T. Ciuleanu2, D. Damjanov3, H. Ganchev4, V. Kanarev5, P. Stella6, N. Cited by

10 - Related articles - View as HTML - All 5 versions

20. Phase III study of pemetrexed plus carboplatin compared with etoposide plus

carboplatin in chemotherapy-naive patients with extensive-stage small-cell lung cancer

ascopubs.org [HTML]… , NA Karaseva, T Ciuleanu, J Jassem, M … - Journal of Clinical …,

2009 - jco.ascopubs.org

From the Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel

Hill, NC; Vrije University Medical Center, Amsterdam; Eli Lilly Netherlands, Utrecht, the

Netherlands; Christie Hospital, Manchester, United Kingdom; US Oncology, Houston, TX;

...


21. Phase II randomized study of trabectedin given as two different every 3 weeks dose

schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum- M

Bidzinski, TE Ciuleanu, T Hogberg, MZ … - Annals of …, 2009 - Eur Soc Med Oncology

Results: ORR was 38.9% [95% confidence interval (CI) 25.9% to 53.1%; arm A] and 35.8%

(95% CI 23.1% to 50.2%; arm B) (intention-to-treat primary analysis). Median time to

progression was 6.2 months (95% CI 5.3–8.6 months; arm A) and 6.8 months (95% CI

4.6–7.4 months; ...


22. A randomised phase II study of OSI-7904L versus 5-fluorouracil (FU)/leucovorin (LV) as

first-line treatment in patients with advanced biliary cancersT Ciuleanu, M Diculescu,

NM Hoepffner, J Trojan … - Investigational new …, 2007 - Springer

Summary The prognosis of advanced biliary tract carcinoma is poor with chemotherapy

limited to a palliative role. This randomised study was designed to evaluate the

effectiveness of a new liposomal thymidylate synthase inhibitor (TSI), OSI-7904L, in

parallel with a modified de ...


23. [CITATION] Darbepoetin alfa (da) 500mcg or 300mcg once every three weeks (q3w) with

or without iron in patients (pts) with chemotherapy-induced anemia (CIA) T Silberstein, T

39

Webb, S Averyanova, T Ciuleanu, L … - Ann Oncol, 2008


24. [CITATION] National Cancer Institute of Canada Clinical Trials Group Shepherd, J

Rodrigues Pereira, T Ciuleanu, EH Tan, V … - … -cell lung cancer. N Engl J …, 2005


25. [CITATION] Central European Cooperative Oncology Group CECOG. Cisplatin and

gemcitabine first-line chemotherapy followed by maintenance gemcitabine or best …R

Ramlau, N Ghilezan, T Ciuleanu, B Cucevic, K … - Lung Cancer, 2006


26. [CITATION] on behalf of the SATURN Investigators. SATURN: A double-blind,

randomized, phase III study of maintenance erlotinib versus placebo following …

27. F Cappuzzo, T Ciuleanu, L Stelmakh, S Cicenas, A … - J Clin Oncol, 2009


28. [CITATION] SATURN: a double blind, randomized, phase III study of maintenance

erlotinib versus placebo following nonprogression with first-line platinum-based

29. F Cappuzzo, T Ciuleanu, L Stelmakh… - Proc Am Soc Clin Oncol, 2009


30. I.D. Postescu, C. Tatomir, G. Cherecheş, I. Brie, G. Damian, D. Petrişor, A-M Hosu, V.

Miclăuş, A. Pop: Spectroscopic characterization of some grape extracts with potential

role in tumor growth inhibition, Journal of Optoelectronics and Advanced Materials,

2007, 9(3), 564-567, i.f. 0.577.

1 citare:Top of Form

Bottom of Form

31. Multi-experimental Characterization of Grape Skin Extractsagriculturejournals.cz [PDF]L

ŠŤAVÍKOVÁ, M POLOVKA, B HOHNOVÁ, J … - agriculturejournals.cz antioxidants: Spin

trapping EPR and optical study. Free Radical Biology and Medicine, 31:43–52. Postescu

ID, Tatomir C., Chereches G., Brie I.. Damian G., Petrisor D., Hosu A.-M., Miclaus V., Pop

A. (2007):

40

32. Spectroscopic characterization of some grape extracts with ... Articole cu conţinut

similar - Afişare ca HTML - Toate cele 7 versiuni

A.Dorhoi, V. Dobrean, M. Zahan, P. Virág. Modulatory effects of several herbal extracts

on avian peripheral blood cell immune responses, Phytother. Res., Vol. 20, 2006, 352-

358, i.f. 1.772.

14citari:http://scholar.google.ro/scholar?cites=15103764961601747767&as_sdt=2005&

sciodt=2000&hl=ro

32. A.Filip, S. Clichici, A. Mureşan, D. Daicoviciu, C. Tatomir, C. Login, S. Dreve, C.

Gherman: Effects of PDT with 5-aminolevulinic acid and chitosan on Walker

Carcinosarcoma. Exp. Oncol., 2008, 30, 3, 212-219, i.f. 0.115.

4citari:http://scholar.google.ro/scholar?cites=14195523122993684921&as_sdt=2005&s

ciodt=2000&hl=ro

33. P.Virág, I. Brie, I.D. Postescu, M. Perde-Schrepler, E. Fischer-Fodor, O. Soriţău, A.

Irimie, V. Cernea. Comparative study of two evaluation methods for the genotoxic

effects of environmental heavy metals on normal cells, Toxicol. Ind. Health, 25 (4-5),

2009, 253-8, i.f. 0.700.

2citari:http://scholar.google.ro/scholar?cites=3589248269522944064&as_sdt=2005&sci

odt=2000&hl=ro

34. Cucuianu A, Patiu M, Rusu A. Hepcidin and multiple myeloma related anemia.

Medical Hypotheses, ISSN 0306-9877, 66:352-354, 2006 – 1 citare: Katodritou E, Terpos E,

Zervas A. et al. Hypochromic erythrocytes (%): a reliable marker for recognizing iron-

restricted erythropoiesis and predicting response to erythropoietin in anemic patients

with myeloma and lymphoma. Ann. Hematol, 2007, 86:352-354

35.WNT4 is expressed in human fetal and adult ovaries and its signaling contributes to

ovarian cell survival

M Jääskeläinen, R Prunskaite-Hyyryläinen, F … - Molecular and cellular …, 2009 –

Elsevier Minna Jääskeläinen a , b , Renata Prunskaite-Hyyryläinen c , d , Florence Naillat

41

c , d , HelkaParviainen f , g , h ... in the regulation of apoptosis in mammalian ovaries

([Inoue et al., 2003] and[Jaaskelainen et al ... HCl in a microwave oven (700 W for 2 min

and 300 W for 15 min) was ...


36.Ronco G, van Ballegooijen M, Becker N, Chil A, Fender M, Giubilato P, Kurtinaitis J,

Lancucki L, Lynge E, Morais A, O’Reilly M, Sparen P, Suteu O, Rebolj M, Veerus P, Primic

Zakelj M, Anttila A. Process performance of cervical screening programmes in Europe.

Eur J Cancer 2009;45(15):2629-2722.

Citări în reviste indexate ISI:

a. Ronco G, Anttila A. Cervical cancer screening in Europe – changes over the last 9 years.

Eur J Cancer 2009;45(15):2629-2631.

b. Anttila A, von Karsa L, Aasmaa A, Fender M, Patnick J, Rebolj M, Nicula F, Vass L,

Valerianova Z, Voti L, Sauvaget C, Ronco G. Cervical cancer screening policies and

coverage in Europe. Eur J Cancer 2009;45(15):2649-2658.

c. De Vuyst H, Clifford G, Li N, Franceschi S. HPV infection in Europe. Eur J Cancer

2009;45(15):2632-2639.

d. Anttila A, Ronco G. Working Group on the Registration and Monitoring of Cervical Cancer

Screening Programmes in the European Union; within the European Network for

Information on Cancer (EUNICE). Description of the national situation of cervical cancer

screening in the member states of the European Union. Eur J Cancer 2009;45(15):2685-

2708.

e. Low Proportion of False-Negative Smears in the Finnish Program for Cervical Cancer

Screening. Stefan Lönnberg1,2, Ahti Anttila1, Laura Kotaniemi-Talonen1, Harry Kujari4,

Jukka Melkko5, Gustav Granroth6, Martine Vornanen7, Timo Pietiläinen8, Anna Sankila3,

Johanna Arola3, Tapio Luostarinen1 and Pekka Nieminen. Cancer Epidemiology

Biomarkers 2009, &Prevention, 2010,;19:381

42

f. Austin M. Onosko A. Druzdzel M. The Pittsburg Cervical Cancer Screening Model. Arch

Pathol Lab Med 2010;134:744-750.

g. PE Castle a , J Bulten b , M Confortini c , P Klinkhamer d , A Pellegrini e , AG Siebers b G

Ronco f , M Arbyn . Age-specific patterns of unsatisfactory results for conventional Pap

smears and liquid-based cytology: data from two randomised clinical trials. BJOG 2010,

VOL 117(9):1067-1073.

37. Anttila A, Ronco G. Working Group on the Registration and Monitoring of Cervical Cancer

Screening Programmes in the European Union; within the European Network for

Information on Cancer (EUNICE). Description of the national situation of cervical cancer

screening in the member states of the European Union. Nicula F, Suteu O, Pais R, Neamtiu

L.Cervical cancer screening in Romania. Eur J Cancer 2009;45(15):2685-2708.

3 citari

Citări în reviste indexate ISI:

a. Arbyn M, Rebolj M, De Kok I.M.C.M., Fender M, Becker N, O’Reilly M, Andrae B. The

challenges of organising cervical screening programmes in the 15 old member states of

the European Union. Eur J Cancer 2009;45 (15):2671-2678.

b. Nicula F. Al, Anttila A, Neamtiu L, Primic Žakelj M, Tachezy R, Chil A, Grce M, Kesić V.

Challenges in starting organised screening programmes for cervical cancer in the new

member states of the European Union. Eur J Cancer 2009; 45(15):2679-2684.

c. Cancer mortality in Europe, 2000–2004, and an overview of trends since 1975

1. C. La Vecchia1,2,

2. C. Bosetti1,*,

3. F. Lucchini3,

4. P. Bertuccio1,

5. E. Negri1,

6. P. Boyle4 and

7. F. Levi3

43

38.Apoptosis in cancer: Key molecular signaling pathways and therapy targets

C Burz, I Berindan-Neagoe, O Balacescu, … - Acta …, 2009 - informahealthcare.com

Apoptosis is a physiological process vital for embryologic development and the maintenance

of homeostasis in multicellular organisms, but it is also involved in a wide range of pathological

processes, including cancer. In mammalian cells, apoptosis has been divided into two ...


39. C BRAICU, I BERINDAN-NEAGOE, VS … - Journal of Food … - interscience.wiley.com

CORNELIA BRAICU1,4, IOANA BERINDAN-NEAGOE1,2, VERONICA SANDA CHEDEA3, LOREDANA

BALACESCU1, IOANA BRIE1, OLGA SORITAU1, CARMEN SOCACIU3 and

ALEXANDRU IRIMIE1,2 1Cancer Institute “I Chiricuta” 34-36 Republicii st. 400015 Cited by 1 -

Related articles

40. [PDF] In vitro evaluation of the chemoprotective action of flavan-3-ols against

deoxynivalenol related toxicityibna.ro [PDF]C Braicu, I Berindan-Neagoe, O Tudoran, O … -

Archiva Zootechnica, 2009 - ibna.ro

In vitro evaluation of the chemoprotective action of ...

Cornelia Braicu 1† , Ioana Berindan-Neagoe 1,2 , Oana Tudoran 1 , ... O. Balacescu 1 , Dumitrita

Rugina 3 , Claudia Gherman 1 , ... 1 Cancer

Institute “I Chiricuta”, Cluj-Napoca, Romania 2 University of Medicine and Pharmacy “Iuliu ...

Cited by 1 - Related articles - View as HTML

41. Protective action of different natural flavan-3-ols against aflatoxin B1-related cytotoxicity, O

TUDORAN, O BALACESCU, I NEAGOE … - Journal of Food … - interscience.wiley.comVet.

Immunol. Immunopathol. 18, 199–209. BRAICU, C., BERINDAN-NEAGOE, I., BURZ, C.,

BALACESCU, O. and IRIMIE, A. 2009a. ... BRAICU, C., BERINDAN-NEAGOE, I., TUDORAN,

O.,BALACESCU, O., RUGINA, D., GHERMAN, C., SOCACIU, C. and IRIMIE, A. 2009b. ...


42. p53 gene therapy using RNA interference.

44

I Berindan-Neagoe, O Balacescu, C Burz, … - Journal of BU ON.: …, 2009 - ncbi.nlm.nih.gov1. J

BUON. 2009 Sep;14 Suppl 1:S51-9. p53 gene therapy using RNA interference.Berindan-Neagoe

I, Balacescu O, Burz C, Braicu C, Balacescu L, Tudoran O, Cristea V, IrimieA. Cancer Institute

I.Chiricuta, Cluj Napoca, Romania. [email protected]. Cited by 1

43. Gene expression profiling of primary cutaneous melanoma and clinical outcome

oxfordjournals.org [HTML]… Ortiz Romero, T Robert, O Balacescu, … - JNCI Journal of the …,

2006 - jnci.oxfordjournals.org

Background: Gene expression profiling data for human primary cutaneous melanomas are

scarce because of the lack of retrospective collections of frozen tumors. To identify differentially

expressed genes that may be involved in melanoma progression and prognosis, we investigated

the ...


Reprezentant legal


Manager




45

ANEXA 4.3 Produse si tehnologii rezultate din activitati de cercetare, bazate pe

brevete, omologari sau inovatii proprii. Studii prospective si tehnologice si

servicii rezultate din activitatea de cercetare-dezvoltare, comandate de

beneficiar

85. 11 x 20 = 220

86. Nicolae Todor Soft pentru evaluarea lezării nucleului prin testul cometei - 2005 –

utilizat în mod curent în cadrul IOCN

87. Nicolae Todor Baza de date pentru calculul timpilor de iradiere si managementul

unei sectii de radioterapie externa -2007 – utilizat în mod curent în cadrul IOCN

88. Nicolae Todor Baza de date pentru elaborarea rezultatelor si managementul unui

platou de imagistica - 2007 – utilizat în mod curent în cadrul IOCN

89. Nicolae Todor Baza de date privind administrarea schemelor de citostatice – 2006 –

utilizat în mod curent în cadrul IOCN

90. Nicolae Todor Baza de date pentru elaborarea rezultatelor si managementul sectiei

de anatomie patologica -2006 – utilizat în mod curent în cadrul IOCN

91. Tehnologia microarray Agilent WHG (2007-prezent) – identificare de noi molecule

in diagnostic molecular- Proiecte de cercetare ; utilizator IOCN proiecte cod: PNII

Breastomics nr contract 42029/2007 ; IDEI ID cod 314/2007 ; Cervixarray 42-

160/2008 ;

92. Tehnologia PCR array (2007-prezent)- identifucare de mecanisme moleculare

deficitare in patologia maligna; utilizator IOCN proiect: de cercetare IDEI ID cod

314/2007

93. Luciana Neamtiu Baza de date pentru elaborarea rezultatelor si managementul

laboratorului de citologie -2008 – utilizat în mod curent în cadrul IOCN

94. Luciana Neamtiu Baza de date si sistem de management pentru programele de

screening populational pentru cancerul de col uterin – 2005

95. Luciana Neamtiu – Sistem informatic pentru managementul Registrul regional de

cancer Nord-Vest – utilizat în mod curent în IOCN

46

Reprezentant legal


Manager




Anexa 5.1. Lucrări ştiinţifice (tehnice) publicate in reviste de specialitate8)

47

41 X 5 PUNCTE =205

2005

1. O. Balacescu, Ioana Neagoe, Roxana Ola, L. Vlase, Marcela Achim, S.E. Leucuta.

Farmacocinetica Doxorubicinei in organe dupa administrare la soareci sub forma libera

si incapsulata in lipozomi. Clujul Medical vol. LXXVIII no.1-2005 – 192-199.

2. O. Balacescu, L. Vlase, Marcela Achim, Ioana Neagoe, Roxana Ola, , S.E. Leucuta. Studii

preclinice de Farmacocinetică asupra Doxorubicinei libere şi încapsulate în lipozomi

(Caelyx). Clujul Medical vol. LXXVIII no.1-2005 – 199-205.

3. Ioana Berindan-Neagoe, O. Balacescu, Rodica Risca, Victor Cristea. Molecule de

adeziune celulara in invazie si metastazare. Evidentierea moleculei E-caderina, produs

al genei CDH1- gena supresoare tumorala. Clujul Medical vol. LXXVIII no.2-2005 pp.

409-415.

4. Daniela Todea, Marina Barsu, Silvia Coroianu, G. Muresan, Luminita Lelutiu, R. Buiga,

G. Laszlo , Angiogeneza in carcinomul in situ, microinvaziv si invaziv al colului uterin –.

Clujul Medical 2: 358-364, 2005.

5. Claudia Ordeanu, V.Cernea, N.Ghilezan: Clinical application of the variation of

dose/fraction used in the brachitherapy of cervical cancer”, articol, Clujul Medical, vol.

LXXVIII, 2005: 343-351

6. Doina Piciu, A Irimie, A.Bara, C.Cebotaru – Radionuclide Treatment of Metastatic Bone

Pain Experience of the I. Oncologic Cluj Napoca; Clujul Medical LXXVIIInr.12005 73-79

7. O. Coza, O. Soriţău, I. Brie, V. Cernea: Predictive assays in radiotherapy: cellular

clonogenic survival (colony assay). Methodology of in vitro measurement, Clujul

Medical, 2005.

2006

48

8. Luciana Neamţiu, A Markov Model in Cervical Cancer Screening Strategy,

Creative Mathematics and Informatics, North University of Baia Mare, Department of

Mathematics and Computer Science, Vol. 16, 2006, ISSN 1584-286X, p. 91-94.

9. Doina Piciu, Cosmin Lisencu, Adela Bara, Florin Stamatian, Carmen Georgescu-

Diagnosis and Treatment of Thyroid Carcinoma in Pregnancy – Case Report –

Romanian Journal of Endocrinology and Metabolism, vol 5 nr 4; 2006 p 25-33

10. Suteu O., Nicula F., Irimie A., Lazar L., Pais R., Duma M., Neamtiu L., Coza D., Farcas

M., “Strategies of cervical cancer prevention in Cluj County, Romania”, Abstracts

Volume pg 440, 6th International Multidisciplinary Congress EUROGIN 2006, Paris, 04 /

2006

11. A. Mureşan, Ş. Suciu, S. Clichici, I. D. Postescu, D. Daicoviciu, N. Pop: Study on the

effect of a grape seed extract in Ehrilch carcinoma, Buletinul Universităţii de Ştiinte

Agricole si Medicină Veterinară, 2006, 63, 114-119.

12. Cucuianu A, Stoia M, Farcas A, Dima D, Zdrenghea M, Patiu M, Olinic D, Petrov L.

Arterial Stenosis and Atherothrombotic Events in Polycythemia Vera and Essential

Thrombocythemia. Rom J Intern Med, ISSN 1582-3296, 44, 4, 397-406, 2006

2007

13. Teodora Sanislav, Ioan Stoian, Dorina Căpăţînă, Mihaela L. Drăgan, Luciana Neamţiu,

Florian Nicula, Ofelia Şuteu, Liana Lupşa, Data Management System for Cervical Cancer

Screening – CanScreen, Acta Electrotehnica, pp. 43-46, ISSN 1841-3323, Volume 48,

Number 4, septembrie 2007, Cluj-Napoca

14. V.Nagy, N.Todor, O.Coza, C.Ordeanu, N.Ghilezan: Quality of life and treatment related

toxicity in 335 patients with locally advancved cervical carcinoma treated by two

chemoradiation regimens; Journal of BUON 12:389-394,

15. C.Ordeanu, O.Coza, S.Gavriş, N.Todor, E.Szilagy, M.Bako, V.Cernea, N.Ghilezan,

V.Nagy: Clinical results of medium dose rate brachitherapy combined with external

beam radiotherapy in the treatment of advanced cervical carcinome; Journal of BUON

12:221-226, 2007

49

16. TE.Ciuleanu, G.Fountzilas, E.Ciuleanu, M.Palataniotis, N.Todor, N.Ghilezan: Paclitaxel

and carboplatin in relapsed or metastatic nasopharyngeal carcinoma: a multyicenter

phase II study; Journal of BUON 9:161-166, 2007

17. P.Rusu, TE.Ciuleanu, D.Cernea, D.Pelau, V.Gaal, C.Cebotaru, T.Gutman, N.Todor,

N.Ghilezan: Concurrent chemoradiotherapy with vinorelbine and platinum compound

followed by consolidation chemotherapy for unresectable stage III non-small cell lung

cancer: Preliminary results of a phase II study; Journal of BUON 12:33-40, 2007

18. Arbyn M, Primic-Zakelj M, Raifu A.O, Grce M., Paraskevaidis E., Diakomanolis E., Kesic

V., Nicula F.A., Şuteu O., Karsa L. The burden of cervical cancer in South-East Europe at

the beginning of the 21st century. Collegium Antropologicum, 2007; 31(2):7-10.

19. Sanislav T., Stoian I., Căpăţână D., Drăgan M., Neamţiu L., Nicula F., Şuteu O., Lupşa L.,

Data Management System for Cervical Cancer Screening – CanScreen, Acta Electronica

2007;48(4):43-46.

20. Eniu A. Integrating biological agents into systemic therapy of breast cancer:

trastuzumab, lapatinib, bevacizumab. J BUON. 2007 Sep;12 Suppl 1:S119-26.

Review.PMID: 17935269

21. Mihaela HEDEŞIU, Luminita LELUŢIU, Sorana D. BOLBOACĂ, V. POPIŢA, T. Guttman,

Mihaela BACIUŢ, Expression of CD44S Cell Adhesion Molecule in Maxillofacial

Squamous Cell Carcinomas and its Imaging Significance, Revista medico-chirurgicala a

Societatii de Medici si Naturalisti din Iasi, Society of Physicians and Natturalist,

Romania, 112(1), 312-319, 2008, [indexată Medline (PubMed, Index Medicus)],ISSN:

0300-8738,

22. A. Horak, R. Buiga, O. Soriţău, S. Neamţu, M. Cucuianu: Acute Megakaryiocytic and

Myelofibrosis. Considerations based on a case report, Clujul Medical, 2007,1,133-7.

23. O. Soriţău, I. Brie, V. Foris, V. Lung-Illes, V. Cernea: Experimental Model for In vitro

Study and Quantification of Neoangiogenesis, Fiziologia – Physiology, 2007, Suppl. 17,

9-10.

24. O. Lucaciu, D. Ciupercescu, G. Băciuţ, O. Soriţău, I. Groza, M. Băciuţ, E. Páll, S. Bran,

H. Rotaru, C. Dinu, C. Balog, B. Crişan, A. Sava, H. Almăşan: Implicarea celulelor stem

50

în regenerarea tisulară şi în procesele de vindecare. Metode de obţinere de celule stem

embrionare, Revista medico-chirurgicală a Societăţii de Medici şi Naturalişti din Iaşi,1,

2007, 3, supl. 1, 967-972, ISSN 00487848.

25. Cucuianu A. Targeting epigenetics and other pathways in the treatment of

myelodysplastic syndromes. Haema, ISSN 1108-2682, 10, Suppl 2, 56-61, 2007

2008

26. Lupşa R., Lupşa L., Neamţiu L., An Optimal Model to Solve the Transport Problem for

Mammography Screening, lucrare publicată în extenso în Proceedings of 2008 IEEE

Internatinal Conference on Automation, Quality and Testing, Robotics (AQTR 2008), p.

139-142, ISBN 978-1-4244-2576-1.

27. Chiorean I., Lupşa L., Neamţiu L., Markov Models for the Simulation of Cancer

Screening Process, lucrare publicată în Numerical Analysis and Applied Mathematics,

International Conference, pag. 143 – 146.

1. I. D. Postescu, M. Achim, P. Virág, C. Tatomir, M. Perde-Schrepler, D. Colcear, I. V.

Cernea. Efectele citoprotectoare, in vitro, ale unui ulei de palmier cu conţinut în

tocotrienoli, Clujul Medical, Vol. 531, 2008: 126-132.

2. E. Páll, I. Groza, C. Tomuleasa, C. Ober, D. Groza: Isolation and cultivation of mouse

mesenchymal stem cells on polypropylenic scaffold, Bulletin of Agricultural Sciences and

Veterinary Medicine, 2008; 65:139-143.

3. E. Páll, I. Groza, O. Soriţău, L. Cătană, M. Cenariu: Modulation of cardiac differentiation

of mouse embryonic stem cells under the influence of some growth factors, Lucrari

ştiinţifice Medicina Veterinară, Ed. Ioan Ionescu de la Brad Iaşi, ISSN 1454-7406, vol.51

(10), 2008,117-122.

4. E. Páll, I. Groza, O. Soriţău, S. Ciupe, L. Cătană: Isolation, culture and identification of

bone cells from newborne rats, Bulletin of University of Agricultural Sciences and

51

Veterinary Medicine Cluj-Napoca, Veterinary Medicine, pISSN-1843-5270, eISSN 1843-

5378, 2008, 65 (1).

28. E. Páll, I. Groza, C. Tomuleasa, C. Ober, D. Groza: Isolation and cultivation of mouse

mesenchymal stem cells on polypropilenic scaffold, Bulletin of University of Agricultural

Sciences and Veterinary Medicine Cluj-Napoca, Veterinary Medicine, pISSN-1843-5270,

eISSN 1843-5378, 2008, 65 (1).

29. Dima D, Cucuianu A, Petrov L. Cytogenetic and molecular response after Dasatinib in

blastic phase chronic myeloid leukemia. Journal of radiotherapy and medical oncology

2008; 14 (2): 126-128- indexat ISI

2009

30. O. Balacescu, I. Neagoe, L. Balacescu, N. Crisan, B. Feciche, O. Tudoran, I. Coman, A.

Irimie. Angiogenesis serum protein quantification for prostate pathology. Current

Urology, 2008; 2: 181-187.

31. Cornelia Braicu, Claudia Burz, Ioana Berindan-Neagoe, Ovidiu Balacescu, Marcel

Tantau, Victor Cristea, Alexandru Irimie. Molecular markers in the pathogenesis of

cholangiocarcinoma: potential for early detection and selection of appropriate

treatment, Vol. 2, No. 3, 2009.

32. Cornelia Braicu, Claudia Burz, Ioana Neagoe, Ovidiu Balacescu, Florin Graur, Victor

Cristea, Alexandru Irimie, Hepatocellular carcinoma: tumorigenesis and prediction

markers, doi:10.4021/gr2009.07.1304, Publish ahead of print July 23, 2009.

33. Cornelia Braicu, Ioana Berindan-Neagoe, Oana Tudoran, O. Balacescu, Dumitrita

Rugina, Claudia Gherman, Carmen Socaciu, Al. Irimie, In vitro evaluation of the

chemoprotective action of flavan-3-ols against deoxynivalenol related toxicity, 2009,

12(32), 45-55

52

34. Rugina D., Pintea A., Braicu C., Farcal L., Andrei S., Socaciu C., 2009, Rosmarinic acid

reduces oxidation of human retinal epithelial cells, Lucrari Stiintifice USAMV Iasi,

52(11), 250-254, ISSN 1454-7406 (B+ CAB).

35. Cornelia Braicu, Ioana Berindan-Neagoe, Claudia Burz, Ovidiu Balacescu, Alexandru

Irimie, Catechins therapeutic implications in cancer, Biology and Theraphy of Cancer

Cell, 1(1), 2009, 81-84

36. C. I. Tomuleasa, O. Soriţău, V. Foris, E. Pall, V. Lung: The influence of different growth

factors on stem cells in culture, Revista de Medicină şi Farmacie, 2009; 55:37-38.

37. Cucuianu A, Dohner K, Dima D, Schlenk R, Schmidt M, Patiu M, Basarab C, Selicean C,

Bojan A, Vasilache A, Urian L, Torok T, Zdrenghea M, Dohner H, Petrov L. The role of

cytogenetics and molecular genetics in the management of acute myeloid leukemia.

Biology and Therapy of Cancer Cell, 1,1, 51-56, 2009

38. Todor N., Cernea I.V., Chis A.: From Passive to Active in the Design of External

Radiotherapy Database at Oncology Institute "Prof. Dr. Ion Chiricuţă" from Cluj-

Napoca, Applied Medical Informatics, 25 (2009), 7-15

39. Todor N., Brie Ioana, Nagy Viorica, Rusu M., Saplacan G.: A mathematical model of

comets in single cell gel electrophoresis technic for evaluation of DNA damage, Annals

of the Tiberiu Popoviciu Seminar of Functional Equations, Approximations and

Convexity, 7 (2009) 219-228

Reprezentant legal


Manager




53

Anexa 5.2.Lucrări ştiinţifice prezentate la conferinţe internaţionale cu comitet de program

159 x 5 = 795

2005

1. Luciana Neamţiu, Databases Applied in Pharmacoeconomic Evaluation, The

Proceedings of the International Conference “The Impact of European Integration on

the National Economy”, Editura Risoprint, 2005, ISBN 973-651-007-0, p.402-406.

2. O. Balacescu, A Kauffmann, I. Neagoe, V Cristea, V. Lazar, G. Vassal. Cisplatin

resistance in ovarian cancer using gene expression microarrays. 17th pezcoller

Symposium. Molecular Understanding of solid tumors. June 16-18, 2005 –Trento,

Italy. in The Pezcoller Foundation Journal, year 13 n.24, pag 24.

3. Ioana Berindan Neagoe, O. Balacescu, Roxana Ola, Al Irimie. APC methylation in

colorectal cancer. 17th pezcoller Symposium. Molecular Understanding of solid

tumors. June 16-18, 2005 –Trento, Italy, in The Pezcoller Foundation Journal, year 13

n.24, pag 27.

4. Ioana Brie, V. Cernea, N.Todor, Maria Perde, Piroska Virag, Eva Fischer, Olga

Soritau, I.D. Postescu, Iolanda Sicoe, Viorica Nagy, N. Ghilezan Prediction by comet

assay of the response to radiotherapy: preliminary results in cervical tumors- The

34th Annual Meeting of the European Society for Radiation Biology (ESRB) and The

Annual Scientific Meeting of the Association for Radiation Research (ARR), Leicester,

Marea Britanie, 5-8 septembrie 2005

5. Chaitchik, O.Soritau, E.Fischer, D.Pelau, L.Lazar, YS Schiffenbauer CellScan

technology for in vitro prediction of tumor response to chemotherapeutic agents,

Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings, 23 (165,

suppl.): 2125

6. V. Cernea, Ioana Brie, Maria Perde, Piroska Virag, Olga Soritau, Eva Fischer, Viorica

Nagy, O. Coza, Iolanda Sicoe, N. Ghilezan - Prediction of the response to radiotherapy

by comet assay: preliminary results in cervical tumors ECCO 13 – The European

54

cancer Conference , Paris, Franta, 30 oct-3 nov. 2005 abstract in European Journal of

Cancer –EJC Supplements, 2005, 3(2

7. Galatir L. M., Duma M.,Valoarea expresiei beta-cateninei si a gradului de diferentiere

histologica – rol prognostic in carcinoamele hepatice ? Al VII-lea Simpozion si Curs

Postuniversitar al Sectiunii Romane a IASG (International Association of Surgeons and

Gastroenterologists) , Bucuresti , 20-22 aprilie 2005

8. Claudia Ordeanu Clinical application of the different size of dose/ fraction in

brachytherapy of the cervical cancer, GEC-ESTRO Meeting, 6-7 mai 2005, Budapesta,

Ungaria

9. Cosaceanu D, R Budiu, Carapancea M, Lewensohn R and Dricu A. Molecular

Pathogenesis of Lung Cancer: Opportunities for Translation to the Clini. Ionizing

radiation activates IGF-1R triggering a cytoprotective signaling by interfering with Ku-

DNA-binding capacity via a P38- dependent mechanism. Poster, February 2005, San

Diego, California, USA.

10. Viorica Nagy, Claudia Ordeanu, O.Coza, N.Todor, N.Ghilezan: Quality of life in

patients with cervical cancer during concomitant radiochemotherapy, rezumat în

Abstract Book ECCO 13, 30 october-3 november 2005, Paris, EJC Supplements,

vol.3(2): 264

2006

11. Luciana Neamţiu, Daniela Coza, Florian Nicula, Ofelia Suteu, Improvement of Data

Quality in Institutional Cancer Registry by Data Linkage, The Role of Cancer Registries

in Suveillance and Cancer Care, pp. 129, Poster, octombrie 2006, Amsterdam

(Olanda)

12. Ratiu A., Anghel M.R., Coza D., Claici C.N., Cazma R., Popescu C., “Transforming

knowledge into action”, Congresul mondial de cancer UICC, 07 / 2006 Washington,

DC, USA



55

Volume pg 440, 6th International Multidisciplinary Congress EUROGIN 2006, Paris, 04

/ 2006

14. Luciana Neamţiu, Daniela Coza, Florian Nicula, Ofelia Suteu, Improvement of Data

Quality in Institutional Cancer Registry by Data Linkage, The Role of Cancer Registries

in Suveillance and Cancer Care, pp. 129, Poster, octombrie 2006, Amsterdam

(Olanda)

15. N. Todor Estimarea intirzierii in analiza supravietuirii – la Seminarul Itinerant

“Tiberiu Popoviciu” de Ecuatii functionale, Aproximare si Convexitate, octombrie 25-

29 2006, UBB Cluj-Napoca

16. O Bălăcescu, I Neagoe, A Kauffmann, T Robert, V Lazar, G Vassal, V Cristea: in vitro

and in vivo ovarian cancer study using microarray gene expression for Cisplatin

resistance. The 17th Intrenational Congress of Anti Cancer Treatment Paris 30.01-

02.02. 2006. in abstract book 17th ICACT 2006; pp 261.

17. I Berindan Neagoe, O Balacescu, V. Cristea, E Neagoe, P Achimas, R Ola, I. Diaconu.

Angiogenesis in ovarian cancer – a molecular profile for genes involved in tumor cells

invasion. The 17th Intrenational Congress of Anti Cancer Treatment Paris 30.01-

02.02. 2006, in abstract book 17th ICACT 2006; pp 261-262

18. O. Balacescu, A Kauffmann, L Vlase, I Neagoe, S.E Leucuta. Improved

pharmacokinetics and modified pharmacogenomics of doxorubicin loaded liposomes

vs. free drug administered in mice. 33rd Annual Meeting of the Controlled Release

Society. Vienna 22-26 July 2006. pp 349

19. O. Balacescu, Neagoe I, Kauffmann A, Lazar V. Microarray pharmacogenomics of

doxorubicin entrapped PEG-liposomes in human xenografts in nude mice. The 3rd

EMBL Biennial Symposium: From Functional Genomics to Systems Biology,

Heidelberg, 14-17 october 2006. In abstract book pp 35.

20. R Budiu, Berindan-Neagoe I, Balacescu O, Dricu A, Albertioni F. Comparison of three

tryphostines for inhibiting three growth factors receptors. The 3rd EMBL Biennial

Symposium: From Functional Genomics to Systems Biology, Heidelberg, 14-17

october 2006. In abstract book pp 38.

56

21. Vlad AM, Diaconu I, Gantt K, Buiga, Neagoe Berindan I, Dricu A, Finn OJ. Tumor

antigens MUC1 and Cyclin B1 is aa markers of progession and malignancy in

endometriosis and ovarian epithelial tumors. Annual Meeting of the American

Association of Immunologists, may 12-16, Boston, 2006 Poster 141.22.

22. Cristea V, Balacescu O, Neagoe I, A. Kauffmann, V. Lazar. Microarray gene expression

for cisplatin resistance in in vitro ovarian cancer. Emerging genomic Biomarkers:

Impact on Drug Discovery and Clinical Practice; Fairmont Victoria, British Columbia,

Canada 7-11 mai 2006.

23. ID Postescu, E.Fischer-Fodor, I.Brie, M.Perde, O.Soritau, G.Chereches, C.Tatomir,

P.Virag Polyphenolic compounds antioxidative capacity of grape extracts - 3rd

Intrernational Conference on Oxidative Stress in Skin Medicine and Biology, Andros,

Grecia, 21-24 sept. 2006.

24. Pall E, Perde-Schrepler M, Soritau O, Brie I, Gocza E Comparison between two

methods of differentiation induction in a mouse embryonic stem cell line European

Summer School „Stem Cells & Regenerative Medicine”, Hydra, Grecia, 15-21 Sept

2006



Volume pg 440, 6th International Multidisciplinary Congress EUROGIN 2006, Paris, 04

/ 2006

26. A.Filip, S.Clichici, A.Joanta, C.Tatomir, G.Chereches, C.Gherman, A.Muresan

Implication of metaloproteases and oxidative markers in the pathogenesis of

varicose disease, 13th Biennal Congress of International Society for Free Radical

Research, Davos, Switzerland,Aug.15-19 2006. Publicat in Free radical research,

2006, 40: 127

27. Claudia Ordeanu, O.Coza, S.Gavris, N.Todor, E.Szilagy, M.Bako: Impact of biological

effective dose (BED) on the survival in 261 patients treated for advanced cervical

carcinoma, poster, ESTRO 25 Conference, 8-12 octombrie 2006, Leipzig, Germania.

57

28. Ioana Berindan Neagoe - Angiogenesis in cancer biology and therapy –International

Summer School - Biogenero – 2-12 iulie 2006- Cancer Institute “Ion Chiricuta” Cluj

Napoca

2007

29. Şuteu P. Şuteu O. Nicula F. A. Coza D. Neamţiu L., Aspecte actuale de epidemiologie

descriptivă a cancerului colorectal în România, Zilele UMF „Iuliu Haţieganu” Cluj

Napoca, 7-8 dec. 2007, Vol. rez. p.41-42.

30. Teodora Sanislav, Ioan Stoian, Dorina Căpăţînă, Mihaela L. Drăgan, Luciana Neamţiu,

Florian Nicula, Ofelia Şuteu, Liana Lupşa, Data Management System for Cervical

Cancer Screening – CanScreen, Meditech 2007, Cluj-Napoca.

31. Luciana Neamţiu, Ioana Chiorean, Multiple Dynamic Programming Applied in

Cervical Screening, ENUMATH 2007, pp. 122, Final Program and Abstracts,

septembrie 2007, Graz (Austria)

32. Adela Ratiu, Milena Duma, Daniela Coza, Luciana Neamtiu, Cristina Stanescu,

Ecaterina Scortanc “assessment of childhood cancer incidence in Romania” Abstract

Book pg 171, 29th Annual Meeting of the International Association of Cancer

Registries, Ljubljana, Slovenia, 17- 20 / 09 2007

33. Liana Lupşa, Ioana Chiorean, Dorel I. Duca, Luciana Neamţiu, Special Efficient

Solutions for Multicriterial Transport Problems, ENUMATH 2007, pp. 122, Final

Program and Abstracts, septembrie 2007, Graz (Austria)

34. Daniela Coza, Florian Nicula, Ofelia Suteu, Luciana Neamţiu, Ioana Rădulescu,

Mihaela Sârbu, Lidia Lovasz, The Role of Cancer Control Department in Our

Comprehensive Cancer Center – Oncological Institute „Ion Chiricuţă”, IACR 29TH

ANNUAL MEETING, Cluj-Napoca, România, Poster, septembrie 2007, Ljubljana

(Slovenia)

35. Luciana Neamţiu, Cost-effectiveness Study for Cervical Screening Program: a

Bayesian Approach, Romanian-German (ROGER) Seminars on Approximation Theory,

Gaermania, 2007

58

36. N. Todor, Relatii intre timpii de supravietuire – la Seminarul Itinerant “Tiberiu

Popoviciu” de Ecuatii functionale, Aproximare si Convexitate, septembrie 26-29

2007, UBB Cluj-Napoca

37. Ovidiu Balacescu. Functional Genomics by microarray technologies .

Pharmacogenomics in ovarian cancer. 1st Conference in New Perspectives in Cancer

Pathology; Bucharest 24-27 mai 2007. abstract book O.P.22.

38. Ioana Neagoe. Tumor angiogenesis. 1st Conference in New Perspectives in Cancer

Pathology; Bucharest 24-27 mai 2007. abstract book I.L.1.3

39. Dumitrita Preda Rugina, Carmen Socaciu, Ioana Berindan Neagoe, Ovidiu Balacescu.

Structure and dose-related stability and antioxidant activity of catechins in abiotic vs

cell environments: HPLC fingerprint and cellular markers. 3rd International

Conference on Polyphenols and Health, 25-28 november 2007 Kyoto, Japan. Poster P

262, abstract book pag 287.

40. Eniu DT, Eniu D, Neagoe I, Brie I, Simon V, Simon S. Clinical application of 90Y Glass

microspheres in oncology: opportunities and risks. 13th general Meeting, 9 may 2007

Neuchatel. Switzerland p 29

41. Cristea V, Berindan Neagoe I, Balacescu O, Budiu R, Ola R, Bujor A, Miron N.

Multiplex laser microarray angiogenesis profiling for detection of ovarian cancer.

Poster Rio de Janeiro

42. Ioana Berindan Neagoe, Liliana Policiuc .FP 7 Health Research. Cooperation between

the EU and the Mediterranean Partners. Functional genomic platform,collaboration

possibilities. Cairo 29-30 oct 2007.

43. Ovidiu Balacescu. Angiogenesis and angiomics in cancer biology and therapy

use of microarray technology. Functional Genomics in Cancer Biology and Therapy-

Biogenero; 27-28 nov 2007 Cluj Napoca.

44. Ioana Berindan Neagoe - The future of therapy in cancer – dr. Ioana Berindan

Neagoe – Cancer Institute Cluj Napoca - International Conference - FUNCTIONAL

GENOMICS IN CANCER BIOLOGY AND THERAPY 28-31 May 2007 Cancer Institute Cluj

Napoca Romania

59

45. Ioana Berindan Neagoe Functional genomics studies related to bioethical conditions

in European Community – International Workshop - Functional Genomics Studies

And Their Validation In Cancer Diagnosis And Therapy - Bioethical Conditions And

European Legislation, Canacer Institute – 4-6 dec 2007

46. Loredana Balacescu- Bioethics in genomics and bioinformatics International

Workshop - Functional Genomics Studies And Their Validation In Cancer Diagnosis

And Therapy - Bioethical Conditions And European Legislation, Canacer Institute – 4-

6 dec 2007

47. O.Balacescu - Microarray technologies in genes panels definiton in ovarian cancer

evolution- International Conference - FUNCTIONAL GENOMICS IN CANCER BIOLOGY

AND THERAPY 28-31 May 2007 Cancer Institute Cluj Napoca Romania

48. Soimita Suciu, A.Muresan, I.D.Postescu, D.Daicoviciu, P. Virag, O.Barbos, I.V.Cernea,

In vitro and in vivo studies on the antitumor efects of polyphenols from vitis vinifera

c.v. Burgund mare , Recas, Romania 3-rd International Conference on Polyphenols

and Health, 25-28 nov.2007, Kyoto, Japonia

49. Ioana Brie, Maria Perde, Piroska Virag, Eva Fischer-Fodor, “Relationship between

cellular radio-sensitivity evaluated by Comet Assay and clinical outcome of patients

with cervix carcinoma treated by radiotherapy” A VII-a Conferinta Internationala de

Comet Assay Universitatea din Ulster, Coleraine, 24-27.06.2007

50. Eva Fischer Fodor, I.D.Postescu, Piroska Virag, Corina Tatomir, M.Tamas, Ioana Brie,

Maria Perde Antimitotic and Antioxydant Effects of Alkaloids from Solanaceae and

Triterpenes from Ericaceea, 2nd International Symposium on Nutrition, Oxygen

Biology and Medicine, Sorbonne, Paris, Franta, 11-13 Apr.2007, Abstract volume:

p.79

51. Piroska Virag, I.D. Postescu, Olga Soritau, Corina Tatomir, Eva Fischer-Fodor,

Gabriela Chereches. Protective Effects of a grape-seeds Hydroalcoholic Extract

(BMR) in the Treatment with Doxorubicin 2nd International Symposium on Nutrition,

Oxygen Biology and Medicine, Sorbonne, Paris, Franta, 11-13 Apr.2007, Abstract

volume

60

52. Bianca Moldovan, Luminita David, Eva Fischer Fodor, Ion Grosu New Solasodine

Derivates with Potential Anticancer Activity SFC07 Congress "Chemistry of the future,

the Future of Chemistry", Paris, 2007, Abstract Book: p54-55,

53. Simina Dreve, Adriana Muresan, Adriana Filip, Doina Daicoviciu, Simona Clichici,

Maria Perde-Schrepler, Rodica Mariana Ion, E.Indrea, TD Silipas Cytotoxic effects of

chitosan-based formulations: in vitro and in vivo experiments EuroNanoForum 2007,

Nanotechnology in industrial applications- European and International Forum on

Nanotechnology, Dusseldorf, 19-21.06.2007, Abstract book, p.311

54. Lung-Illes V, Foris V, Brie I, Soritau O, Perde M, Virag P, Fischer E In vitro evaluation

of lymphocytes radiosensitivity in patients with cervix carcinoma using micronuclei

and comet assay 18th European Students’ Conference, Promising Medical Scientists

Willing to Look Beyond, Charite- Universitatsmedizin, Berlin, Germany, 7-11Oct.

2007. Abstract book, p.150.

55. V. Foris, I. Brie, O. Soritau, V. Piroska, M. Perde, E. Fischer Evaluation by comet

assay of lymphocytes’ in vitro radiosensitivity in healthy women and patients with

cervix carcinoma - 14th International Student Congress of Medical Sciences,

University Medical center Groningen, The Netherlands, 6-9 Iun. 2007, Abstract book,

p. 268

56. Radiobiology Research Center in Cancer Institute Cluj, Romania, V. Cernea, Ioana

Neagoe, Ioana Brie, O. Balacescu Olga Soritau, Maria Perde, A. Irimie,

Experimentelle Strahlentherapie und Klinische Strahlenbiologie, Proceedings des 16.

Symposiums, Dresden, 2007 ISSN 1432-846XX, p. 28-31

57. Cucuianu A. Targeting epigenetics and other pathways in the treatment of

myelodysplastic syndromes.18th Annual Congress of the Greek Society of

Hematology, November 14-17, 2007, Thessaloniki, Greece

2008

58. Neamţiu L., Chiorean I., Lupşa L., Model of Multiple Lexicographical Programming

Applied in Cervical Cancer Screening, în Kunich Karl, Of G., Steinbach O. (Editors),

Numerical Mathematics and Advanced Applications, Springer-Verlag, 2008, p. 91-98.

61

59. Radu Lupşa, Liana Lupşa, Luciana Neamţiu, An Optimal Model to Solve the Transport

Problem for Mammography Screening, AQTR, Cluj-Napoca, Romania, 2008.

60. Luciana Neamţiu, Ioan Stoian, Teodora Sanislav, Dorina Căpăţînă, Florian Nicula,

Ofelia Şuteu UICC World Cancer Congress, Geneva, Elveţia, CANSCREEN – FAIL-SAFE

SYSTEM FOR DIAGNOSIS QUALITY CONTROL IN CANCER SCREENING, publicată ca şi

rezumat în Supplement of the International Journal of Cancer, 2008.

61. Liana Lupşa, Dorel I. Duca, Ioana Chiorean, Luciana Neamţiu, A Model of Dynamic Bi-

level Transportation Problem, 6th INTERNATIONAL CONFERENCE ON APPLIED

MATHEMATICS Baia-Mare, Romania, 2008.

62. Ioana Chiorean, Liana Lupşa, Luciana Neamţiu, Markov Models for the Simulation of

Cancer Screening Process, ICNAAM 2008 (International Conference on Numerical

Analysis and Applied Mathematics), Grecia, 2008.

63. Liana Lupşa, Lucia Blaga, Luciana Neamtiu, A Model of a Lexicographic Bi-criteria

Dynamic Transport Problem, The Twelfth International Conference on Applied

Mathematics and Computer Science, Baisoara, Romania, 2008.

64. Albu C. Bardoş M. Şuteu O. Vladu C. Campania de informare, educare, schimbare de

comportamente din cadrul programului de screening organizat pentru depistarea

cancerului de col uterin – parte a componentei de prevenţie secundară din cadrul

Planului Naţional de Cancer. Conferinţa naţională cu participare internaţională –

Calitatea europeană în medicina familiei. 7-8 nov. 2008, Bucureşti. Vol. Rez. P. 34.

65. FA. Nicula. Neamţiu L. Şuteu O. Păiş R. Model de organizare a unui program regional

de screening al cancerului de col uterin – experienţa pilotului regional Cluj după

prima rundă de 5 ani de screening organizat în perioada 2003-2007. Conferinţa

Naţională de SănătatePublică cu participare internaţională – Prezent şi viitor în

Sănătatea Publică din România. 12-14 nov. 2008, Timişoara. Vol. rez. P.39.

66. Coza D. Claici C. Nicula F.A. Neamţiu L. Şuteu O. Registrul de cancer în România – la

răscruce de drumuri. Conferinţa Naţională de SănătatePublică cu participare

internaţională – Prezent şi viitor în Sănătatea Publică din România. 12-14 nov. 2008,

Timişoara. Vol. rez. p. 40.

62

67. P. Virag, M. Perde-Schrepler, I. Brie, E. Fischer-Fodor, O. Soritau, C. Tatomir, G.

Chereches, I.D. Postescu. Comparative study of two methods of evaluation genotoxic

effects of environmental heavy metals on normal cells, First International Conference

on Environmental Stressors in Biology and Medicine, University of Siena, Siena, Italy,

june 4-6, 2008: 88.

68. V. Foris, V. Lung Illes, C. Tomuleasa, E. Fischer Fodor, P. Virag, M. Perde, O. Soritau,

V. Nagy, V. Cernea: Comet assay and micronuclei assay as tools for studying the

relationship between chronic exposure to heavy metals and genomic lesions, 16th

Annual International Ain Shams Medical Students’ Congress, 16th-18th February

2008, Cairo, Egypt.

69. S. Clichici, M. Perde-Schrepler, A. Filip, D. Daicoviciu, P. Virag, E. Fischer-Fodor, I.

Brie, R. Mariana Ion, C. Loghin, A. Muresan. In vitro and in vivo assessment of the

efficiency of phtotodynamic therapy with tetrasulphophenil-porphyrin, Fiziologia

physiology, vol 18, 2 (58), Congress of the Romanian Society of Physiological

Sciences, Cluj-Napoca, Romania, june 5-7, 2008:17-18.

70. I.D. Postescu, P. Virag, M. Achim, C. Tatomir, E. Fischer-Fodor, O. Soritau.

Modulatory activity of antioxidants in associated treatments with Doxorubicin,

Fiziologia physiology, vol 18, 2 (58), Congress of the Romanian Society of

Physiological Sciences, Cluj-Napoca, june 5-7, 2008:59.

71. C.I. Tomuleasa, O. Soritau, D.R. Ciuca, S. Susman, E. Pall, E. Fischer-Fodor, M.

Perde-Schrepler, P. Virag, I. Brie, V. Lung-Illes, V. Foris. Immunocytochemical

characterization of human mesenchymal stem cells, Fiziologia physiology, vol 18, 2

(58), Congress of the Romanian Society of Physiological Sciences, Cluj-Napoca, june

5-7, 2008:17-18.

72. C.Tatomir, G.Chereches, D. Daicoviciu, I.D.Postescu: Antioxidant and antiinvasive

activity of grape seed (vitis vinifera) extract. The 10-th Congress of the Romanian

Society of Physiological Sciences, Cluj-Napoca, 5-7 June, 2008, Fiziologia, 2008,18

(abstract)

63

73. T. Dicu, V. Foris, I. Brie, I. V. Cernea, I. D. Postescu, Protective effects of L-cysteine

against 60 Co X-rays induced damages in human lymphocytes, Fiziologia physiology,

The 10-th Congress of the Romanian Society of Physiological Sciences, Cluj-Napoca,

june 5-7, 2008, 22.

74. A.Mureşan, Ş. Suciu, I. D. Postescu, G. Damian, D. Colcear, N. Pop, M. Paul,

Experimental study regarding the antioxidant and antitumor activity of naturally

occuring polyphenols, Fiziologia physiology, The 10-th Congress of the Romanian

Society of Physiological Sciences, Cluj-Napoca, june 5-7, 2008, 50.

75. G. Damian, D. Petrişor, V. Miclăuş, C. Cimpoiu, A. Hosu, I. D. Postescu, EPR

investigations of antioxidant activity of some grape skin and seed extracts, Fiziologia

physiology, The 10-th Congress of the Romanian Society of Physiological Sciences,

Cluj-Napoca, june 5-7, 2008, 20.

76. L. I. Sabău, D. Daicoviciu, A. Mureşan, I. D. Postescu, R. Moldovan, The effects of red

grapes polyphenols in female rats with experimentally induced menopause, Fiziologia

physiology, The 10-th Congress of the Romanian Society of Physiological Sciences,

Cluj-Napoca, june 5-7, 2008, 64.

77. I.Chiş, R. Simedrea, M. I. Ungureanu, A. Mureşan, N. Giurgea, I. D. Postescu, A.

Marton, N. Decea, Liver tissue oxidative stress and the role of polyphenols

administration in a rat model of diabetes mellitus, Fiziologia physiology, The 10-th

Congress of the Romanian Society of Physiological Sciences, Cluj-Napoca, june 5-7,

2008, 16.

78. C.Tatomir, I.D.Postescu, Virag P., T.Dicu, E Fischer-Fodor, I. Brie, M.Perde-

Schrepler, G.Chereches. In vitro cytoprotective and radioprotective effects of a whey

protein isolate, (WPI). The 4-th Conference of the Romanian Association of Medical

Laboratories, Cluj-Napoca,18-21 iunie, 2008, Rev.Rom Med. Lab.11(2), supl.27-28,

2008

79. L.Sabau, G.Damian, D.Daicoviciu,A.Muresan, I.D.Postescu, D.Mihu,C.Mihu, In vivo

study regarding antioxidant effect of a grape polyphenol extract using

64

biochemicaland FTIR methods, 3-rd Internat Symp.Advanced spectroscopy on

biomedical and nanostructured systems, Cluj-Napoca, sept 7-10, 2008

80. I. Haiduc, I. Silaghi Dumitrescu, Z. Garban, E. Fischer Fodor, R. Silaghi Dumitrescu,

Metallomics. Metal Elements in Environment, Medicine and Biology, ISSN 1583-4204,

Tome VIII: Proceedings of the 8th International Symposium on Metal Elements in

Environment, Medicine and Biology, Romanian Academy, Timisoara, 2008.

81. E. Fischer Fodor, N. Miklasova, P. Virag, C. Tatomir, I. Brie, M. Perde, V. Cernea, L.

Silaghi Dumitrescu, Biologic evaluation of platinum and palladium complexes using

the static cytometry. Metal Elements in Environment, Medicine and Biology, ISSN

1583-4204, Tome VIII: Proceedings of the 8th International Symposium on Metal

Elements in Environment, Medicine and Biology, Romanian Academy, Timisoara,

2008.

82. M. Perde-Schrepler, I. Brie, P. Virag, I.D. Postescu, O. Soritau, E. Fischer-Fodor, G.

Chereches, C. Tatomir, S. Dreve. Effects of chitosan nanoparticles on the uptake and

phototoxicity of delta-aminolevulinic acid. Abstracts of the 34th Meeting of the

American Society for Photobiology, 2008: 65-66.

83. E. Fischer-Fodor, M. Perde-Schrepler, I. Brie, P. Virag, C. Tatomir, N. Moldovan, L.

Silaghi-Dumitrescu. Antiproliferative Effect and Genotoxicity of Novel Synthesized

Palladium Complexes with Organoarsine Ligands, Quatrieme conference

internationale sur les metaux et la genetique, Faculte de Pharmacie, Universite Paris

Descartes, Paris, 21-24 juillet, 2008: 48.

84. C. I. Tomuleasa, O. Soriţău, V. Foris, V. Lung-Illes, I. Brie, E. Fischer-Fodor, M. Perde-

Schrepler, P. Virág, I.D. Postescu, G. Cherecheş, D. Piciu: Osteoblast differentiation

and immunochemical characterisation of human mesenchymal stem cells, Liječnički

Vjesnik, 2008, 130, Suple. 5, 66.

85. V. Nagy, I. Brie, A. Rancea, N. Todor, C. Ordeanu, O. Coza, A. Traila, M. Perde-

Schrepler, P. Virag, E. Fischer-Fodor, Relationship between in vitro tumor cells

radiosensitivity evaluated by Comet Assay and tumor response to radiochemotherapy

65

in partients with cervix carcinoma, ASTRO 27 Congress, sept 14-18 2008, Goteborg,

Sweden.

86. N. Todor, I. Brie, V. Nagy, M. Perde, G. Saplacan, A computerized morphometric

system for comet assay, Proceedings of the 8th international conference on technical

informatics – CONTI- Timiosara, 5-6 iunie 2008, Automation and applied informatics,

ISSN 1844-539X: 183-186.

87. Cucuianu A. The 2008 WHO Classification of Acute Myeloid Leukemias. The impact

on diagnosis and therapeutic decision making. 2nd Congres of the Romanian

Association of Medical laboratories with International Participation, 25-27 June 2010,

Mamaia, Romania

88. Patiu M., Bacarea A.,Dascalu A., Nicorici C., Cucuianu A. : Myeloid sarcoma. Report of

three cases and rewiew of the literature. 4thRAML Conference with International

Participation 18-21 june 2008 Cluj-Napoca Romania –Abstract published in Revista

Romana de Medicina de Laborator, vol 11,nr 2, iunie 2008 Supliment pg 16-17

89. O. Balacescu, I Neagoe, I Coman, N Crisan, B. Feciche, L. Balacescu, O. Tudoran, C.

Burz, R Suharoschi. A good correlation between DD3PCA, hTERT, GDF15 and PSME

gene expression for prostate cancer diagnosis. International Congress for Anticancer

Treatment (ICACT) Paris, 5-8 februarie 2008. Poster PO 130, p224.

90. I Neagoe, V.Cristea, O. Balacescu, O.Tudoran, R.Budiu, R.Ola, L.Balacescu, A.Bujor,

N.Miron. Multiplex laser based microarray angiogenesis profiling for detection of

ovarian cancer. International Congress for Anticancer Treatment (ICACT) Paris, 5-8

februarie 2008. Poster PO 142, p251.

91. O.Tudoran, I Neagoe, O. Balacescu, R.Budiu, P.Achimas, V.Cristea The evaluation of

molecular profiling of angiogenesis markers in patients with ovarian cancer.

International Congress for Anticancer Treatment (ICACT) Paris, 5-8 februarie 2008.

Poster PO 155, p258.

92. L.Balacescu, O. Balacescu, I Neagoe, V.Cristea, A.Kauffmann, V.Lazar Apoptosis

inhibition by tumor angiogenesis mechanisms in ovarian cancer. Bioinformatic study

66

involving microarray gene expression. International Congress for Anticancer

Treatment (ICACT) Paris, 5-8 februarie 2008. Poster PO 241, p334

93. C.Burz, C.Tanaselia, I Neagoe, O. Balacescu, M.Ursu, A.Gog, L.Vlase, D.Leontin,

M.Chintoanu, S.E.Leucuta, V.Cristea, Clinical Pharmacokineticsof Oxaliplatin in colon

cancer patients International Congress for Anticancer Treatment (ICACT) Paris, 5-8

februarie 2008. Poster PO 68, p206

94. C Burz, B.I. Neagoe, O. Balacescu, O. Tudoran, S. Leucuta, V. Cristea, A. Irimie

Genomic analysis of gene involved in platinum compound resistance. Annals of

Oncology, Volume 19, Supplement 8, September 2008 viii55 - abstract publicat in

revista ISI.

95. Neagoe Berindan Ioana, Balacescu O, Tudoran Oana, Dronca Eleonora, Burz

Claudia, Irimie Al, Cristea V –Terapia antiangiogenica prin utilizarea ARN interferentei

in controlul postranscriptional al expresiei genelor. Comunicata - A 38-a conferinta

anuala de Imunologie, 24-26 septembrie 2008, Busteni, Romania (pag 68-69).

96. Nedelea Irena , Neagoe Berindan Ioana , Cristea V, Burz Claudia , Seiceanu Andrada,

Balacescu O, Balacescu Loredana, Tudoran Oana, Dronca Eleonora – Evaluarea prin

protein array a citokinelor proinflamatorii in cancerul pancreatic versus pancreatita

cronica Comunicata – A 38-a conferinta anuala de Imunologie, 24-26 septembrie

2008 , Busteni, Romania (pag 69-70).

97. Burz Claudia, Neagoe Berindan Ioana, Balacescu O, Nedelea Irena, Tanasila C, Ursu

M, Vlase L, Leucuta S, Irimie A, Cristea V. Oxaliplatin in cancerul colorectal- mecanism

de actiune si parametrii farmacologici. Comunicata la A 38-a conferinta anuala de

Imunologie, 24-26 septembrie 2008 , Busteni, Romania (pag 70- 71).

98. Irena Nedelea, Cristian Nicolae Manea , Claudia Burz, Dan Stanca, Ovidiu Mestes ,

Ovidiu Balacescu, Ioan Coman, Victor Cristea. Molecular mechanisms of chronic

kidney graft loss by interstitial fibrosis and tubular atrophy, Comunicata -The XXth

International Symposium of Morphological Sciences (ISMS), Timisoara, 2008 in

abstract book.

67

99. Irena Nedelea, Claudia Burz, Ioana Neagoe, Loredana Balacescu, Ovidiu Balacescu,

Oana Tudoran, Eleonora Dronca, V.Cristea. Protein array evaluation of

proinflammatory cytokines in pancreatic cancer versus chronic pancreatitis,

Comunicata International Conference of cellular and tissue comparative pathology,

Cluj Napoca, 2008 in abstract book.

100. O. Balacescu, I. Neagoe, N. Crisan, B. Feciche, L.Balacescu, O.Tudoran, A. Irimie,

C. Burz, R. Suharoschi, I. Coman, - Comunicata Aplicatiile reactiei de PCR cantitativ

(QRT-PCR) pentru diagnosticul molecular in cancerul de prostata – Simpozion

National VIASAN CEEX ( Modulul I) , 28-30 septembrie 2008, Sinaia, Romania 59 –

poster

101. Sebestyen Gh., Saplacan G., Rusu M.,Todor N.: Food production monitoring

system for quality and traceability assurance, MicroCAD2008- Nemzetközi

Tudományos Konferencia - International Scientific Conference, pp.125-132, 20-21

March 2008, Miskolc, HUNGARY

102. Gheorghe Sebestyen , Sergiu Nedevschi, Gavril Saplacan , Mihai Cerghizan ,

Nicolae Todor and Mircea Rusu, Towards a Traceability Solution on the Food Supply

Chain, CONTI’2008 The 8th INTERNATIONAL CONFERENCE ON TECHNICAL

INFORMATICS, pp. 121-126, 5-6 June 2008, Timisoara, Romania

103. Nicolae Todor, Saplacan Gavril, Dan Radulescu: semiparametric methods to

evaluate the relationship between survival times, sectiunea poster, International

Biometric Conference, 13 – 18 July 2008, Dublin, Irlanda

104. Gheorghe Sebestyen, Sergiu Nedevschi, Gavril Saplacan, Mihai Cerghizan,

Nicolae Todor, Mircea Rusu: FOODTRACE-Food Quality Control and Traceability

Framework - Scientific Bulletin of The “POLITEHNICA” University of Timisoara,

Romania; Tom 53(67), Fascicola2, 2008, ISSN 1224-600X, pp 115-122

2009

105. Luminiţa Leluţiu “The 12th Romanian-Hungarian Meeting of Pediatric Oncology”,

23-24 octombrie 2009, Cluj-Napoca; lucrarea prezentata: BCR-ABL Positive Chronic

68

Myeloid Leukemia in Infancy – G. Popa, Cristina Blag, Dana Olosutean, Mirela Marian,

Manuela Sfichi, Anca Ilea,;

106. Guran Adriana Mihaela, Moldovan Grigoreta Sofia, Neamtiu Luciana, O abordare

centrata pe utilizator in dezvoltarea unui sistem inteligent pentru generarea

Registrelor Nationale de Cancer, Conferinta Nationala de Interactiune Om-Calculator,

Matrix Rom, Editor: Dorian Gorgan, Adriana-Mihaela Guran, 2009, P. 77-83.

107. Rodica Pais, Mihaela Galatar, Luciana Neamtiu, Ioana Neagoe, Ovidiu Balacescu,

Florian Nicula HPV PCR and liquid based cytology use in cervical cancer preinvasive

lesions triage / poster , Zilele IOCN , Cluj Napoca, 30 Septembrie 2009 - 3 Octombrie

2009 , CLuj Napoca

108. 2. Florian Al. Nicula, Luciana Neamtiu, Mihaela Galatar, Rodica Pais, Ofelia

Suteu “ Ion Chiricuta “ Cancer Institute Department of Prevention and Cancer

Control- one of the oldest cervical cancer prevention management units in Europe,

Zilele IOCN , Cluj Napoca, 30 Septembrie 2009 - 3 Octombrie 2009 , CLuj Napoca

109. Daniela Coza1, Florian Nicula1, Luciana Neamţiu1, Ofelia Şuteu1,2, Lidia

Lovasz1, Mihaela Sîrbu1,AnnaMaria Marton1 LOCUL REGISTRULUI DE CANCER ÎN

ISTORIA INSTITUTULUI ONCOLOGIC “ION CHIRICUŢĂ” Zilele IOCN , Cluj Napoca, 30

Septembrie 2009 - 3 Octombrie 2009 , CLuj Napoca

110. Luciana Neamţiu, Florian Nicula Sisteme informatizate pentru management de

date în programul de control al cancerului- Zilele IOCN , Cluj Napoca, 30 Septembrie

2009 - 3 Octombrie 2009 , CLuj Napoca

111. Coza D. Nicula F. Neamţiu L. Şuteu O. Sârbu M. Lovasz L. Marton A. The role of

NW Regional Cancer Registry from Oncological Institute „Prof. Dr. I. Chiricuţă” Cluj, in

cancer control. Workshop: Priorities for the fight against cancer: responses of the

national and regional healthcare systems. The Latin Association for Health Systems

Analyses. 28-30 May 2009, Constanţa. Vol. Rez. p. 24.

112. Luciana Neamtiu: Modèle de gestion des données dans un Registre Cancer

Régional: le Registre Cancer de la Région Nord-Ouest, prezentare orala, in cadrul

69

Atelier de l’ALASS Priorités dans la lutte contre le cancer: réponses des systèmes

sanitaires régionaux et nationaux, Constanta (Mamaia) Roumanie, 29 - 30 mai 2009;

113. Coza D. Nicula F.A. Neamţiu L. Şuteu O. First year of planning and

implementation of regional cancer registration in North-West region of Romania. 3rd

International cancer Control Congress, 8-11 november 2009, Cernobbio, Como, Italy.

Vol. Rez. p.44.

114. Nicula F. Coza D. Neamţiu L. Claici C. Ungureanu C. Cancer control in Romania –

regional traditional resources and today strategies in cancer registry and screening.

3rd International cancer Control Congress, 8-11 november 2009, Cernobbio, Como,

Italy. Vol. Rez. p. 44

115. Claici C. Ungureanu C. Chicin G. Coza D. Brehar- Cioflec D. Cozma R. Domnariu C.

Cancer surveillance and control system in Romania. 3rd International cancer Control

Congress, 8-11 november 2009, Cernobbio, Como, Italy. Vol. Rez. p. 44-45

116. Luciana Neamtiu, Daniela Coza, Florian Nicula: Computerized Sources of Data –

a Useful Tool for Cancer Registration in the Nord-West Regional Cancer Registry,

poster in cadrul 3rd International Cancer Control Congress, Cernobbio, Italia 8-11

nov. 2009

117. Ronco G. Balegooijen M. Becker N. Chil A. Fender M. Giubilato P. Kurtinaitis J.

Lancucki L. Lynge E. Morais A. O’Reilly M. Sparen P. Suteu O. Rebolj M. Veerus P.

Primic Zakelj M. Anttila A. Extension and process performance of European cervical

cancer screenning programmes. The 25th International Papillomavirus Conference,

May 8-14 2009, Malmö, Sweden.

118. Claici C. Nicula F. Coza D. Fekete E.J. Anticancer strategies – Romanian resources

for action and controversies. Vol. rez. P.115-116. A XXXIV-a Întâlnire Grell, Lugano,

Elveţia, 20-22 mai 2009

119. Daniela Coza. Ratiuni si actiuni in organizarea Registrului National al Cancerelor

la Copil.The 12-th Romanian-Hungarian Meeting of Pediatric Oncology, 23-24

October 2009, Cluj Napoca

70

120. Camelia Nicoleta Claici, Florian Alexandru Nicula, Daniela Coza, Edit Julia Fekete,

“Anticancer Strategies – Romanian Resources for Action and Controversies”, Volum

de rezumate, pag 115-116, a XXXIV- a intalnire GRELL (Grupul Registrelor Cancer de

Limbă Latină), Lugano, 20-22 mai 2009

121. I.D.Postescu, T.Dicu, G.Chereches, A.Filip, C.Tatomir, M.Perde Schrlepler: A

procedure to measure the antioxidant properties of polyphenolic compounds with

DPPH∙ radical assay; biological applications.II nd International Conference of

Oxidative Stress „Havana- Redox 2009, Havana, Cuba, January 29-31, 2009, Rev.

Cubana Farm. 43, (supple 1), 2009, p.20

122. A. Filip, S. Clichici, R.M. Ion. D. Daicoviciu, T. Mocan, C. Tatomir, L. Rogojan, D.

Olteanu, A. Muresan: Self-organized functional materials in photodinamic therapy

cancer, Simpozionul al VII-lea "Mecatronica si inginerie mecanica, microtehnologii si

materiale noi" Revista Romană de Mecanică Fină, Optică şi Mecatronică, Tirgoviste

2009 (rev. Cat.B) ISSN-1584-5982

123. A.-V. Sitar-Tăuţ, M. Cebanu, O. Soriţău, C. Stugren, D. Pop, D. T. Zdrenghea: A

comparison between adhesion molecules (as markers of inflammation) in identifying

cardiovascular disease in postmenopausal women, 2009, Endocrine Abstracts, 20,

P366.

124. E. Fischer Fodor, R. Buiga, D. Pelau, C. Lisencu, P. Virag, C. Tatomir, O. Soritau,

In vitro chemosensitivity testing of tumor cells treated with platin-based drugs. Metal

Elements in Environment, Medicine and Biology, Tome IX, Romanian Academy, 2009:

116-121, ISSN 1583-4204

125. V. Foris, C. Tomuleasa, O. Soritau, V. Lung-Illes, I. Brie, V. Cernea: Comet Assay

as a tool for evaluating radiosensitivity of Mesenchymal Stem Cells, 2nd International

Medical Congress “ASKLEPIOS” 7th-10th May 2009, Sibiu, Romania.

126. V. Foris: Evaluation of stem cells radiosensitivity on ionizing radiation, 4th

International Medical Students' Congress in Novi Sad 16th-19th July 2009, Novi Sad,

Serbia.

71

127. Muresan, A., Suciu, S., Ghibu, S., Daicoviciu, I.D Postescu, I.D., Login, C.The

effect of red grapes polyphenols on antioxidant enzymes in rats exposed to hypobaric

hypoxia, 11-th Regional conf. On Enviroment and Health, 15-16, Mai 2009, Szeged,

Hungary

128. A.Mureşan, S. Suciu, S. Ghibu, D. Daicoviciu, I. D. Postescu, C. Login,

Experimental study regarding the effects of hypobaric hypoxia on some antioxidant

enzymes, A 23-a Conferinţă Naţională a Societăţii Române de Ştiinţe Fiziologice,

Fiziologia physiology, 2009, Suppl, ISSN 1223-2076, 34-35.

129. S. Suciu, A. Mureşan, D. Daicoviciu, S. Clichici, I. D. Postescu, A. Ceban,

Experimental study on the antioxidant effects of polyphenols in Ehrlich ascites

carcinoma, A 23-a Conferinţă Naţională a Societăţii Române de Ştiinţe Fiziologice,

Fiziologia physiology, 2009, Suppl, ISSN 1223-2076, 47.

130. C. Cuceu, D. Ciorba, E. Fischer-Fodor, C. Cosma, D. Marcu, Senzitivitatea de

expunere la Radon si cancerul pulmonar, Zilele Institutului Oncologic „Prof Dr. Ion

Chiricuta”- 80 de ani de lupta impotriva cancerului, 2009, 35.

131. C. Tomuleasa, O. Soritau, E. Pall, S. Susman, D. Rus, C. Mihu, R. Buiga, V. Foris,

C. Iancu: Isolation of liver cancer stem cells a hepatocellular carcinoma biopsy. Zilele

Institutului Oncologic “Prof.Dr.Ion Chiricuta”, 80 de ani de lupta impotriva cancerului,

1-3 oct 2009

132. D.Rus, O. Soritau, S. Susman, C. Mihu : Celulele stem placentare : comoara ce se

arunca. Zilele Institutului Oncologic “Prof.Dr.Ion Chiricuta”, 80 de ani de lupta

impotriva cancerului, 1-3 oct 2009

133. E. Fischer-Fodor, P.Virag, C. Tatomir, L. Silaghi-Dumitrescu: Organometal

compounds applied as radiopharmaceuticals. Zilele Institutului Oncologic

“Prof.Dr.Ion Chiricuta”, 80 de ani de lupta impotriva cancerului, 1-3 oct 2009

134. V. Foris, T.Dicu, I.D.Postescu, I.Brie, E. Fischer-Fodor, V.Cernea, M.Moldivan, C.

Cosma: The effect of a Grape Seed Extract on Radiation-Induced DNA Damage in

Human Lymphocites. Zilele Institutului Oncologic “Prof.Dr.Ion Chiricuta”, 80 de ani de

lupta impotriva cancerului, 1-3 oct 2009

72

135. G.Chereches, C.tatomir, D.Daicoviciu, I.D.Postescu: Antioxidant activity of a

natural Red-Grape Seed Extract (BMR). Zilele Institutului Oncologic “Prof.Dr.Ion

Chiricuta”, 80 de ani de lupta impotriva cancerului, 1-3 oct 2009

136. M. Perde-Schrepler, O.Barbos, I.Brie, C. Tatomir, I.D.Postescu: Protective effects

of Calluna Vulgaris on UVB-irradiated keratinocytes. Zilele Institutului Oncologic

“Prof.Dr.Ion Chiricuta”, 80 de ani de lupta impotriva cancerului, 1-3 oct 2009

137. O. Barbos, P.Virag, T.Dicu, C. Tatomir, E. Fischer-Fodor, I. Brie, M. Perde-

Schrepler, V.Cernea, I.D.Postescu: The cyto and radioprotective effects of a Whey

Protein Isolate. Zilele Institutului Oncologic “Prof.Dr.Ion Chiricuta”, 80 de ani de lupta

impotriva cancerului, 1-3 oct 2009

138. O.Soritau, V.Foris, D.Todea, I. Brie, V.Lung-Ilies, C. Tomuleasa, O.Barbos,

B.Pitea, T.Pop, V.Cernea, R.Badea; In vitro study of tumor angiogenesis in

hepatocarcinoma. Zilele Institutului Oncologic “Prof.Dr.Ion Chiricuta”, 80 de ani de

lupta impotriva cancerului, 1-3 oct 2009

139. I.-C.Brie, V. Nagy, N. Todor, P. Virag, M. Perde-Schrepler, E. Fisher-Fodor, V.

Foris, O. Coza, G. Kacso, C. Ordeanu, A. Rancea: Determinarea preterapeutica a

radiosensibilitatii celulelor tumorale prin testul cometei – metoda de predictie a

raspunsului clinic la radio-chimioterapie in cancerul de col uterin, Conferinta

Societatii Romane de Radioterapie si Zilele medicale ale Institutului Oncologic

“Prof. Dr. Al. Trestioreanu” Bucuresti, Poiana Brasov, 17-19. 09. 2009.

140. I.-C. Brie, V. Nagy, N. Todor , P. Virag, M. Perde-Schrepler, E. Fisher-Fodor, V.

Foris, O. Coza, G. Kacso, C. Ordeanu, A. Rancea: Radiosensibilitatea celulara

intrinseca – factor de predictie a raspunsului la radiochimioterapie in cancerul de col

uterin, Conferinta Nationala “Zilele Oncologiei Ieşene” – Progrese in terapiile

cancerului: tendinte, oportunitati, controverse, Iaşi, 3 – 5 decembrie 2009.

141. Cucuianu A, Precup R. A Hypothetical Mathematical Model of Acute Myeloid

Leukemia Pathogenesis. Poster Presentation, 14th European Hematology Association

Congress, Berlin, 2-6 Iunie 2009

73

142. Mariana Patiu, Selicean Elena-Cristina, Filipas Cristina, Nastase Violeta, Cucuianu

Andrei: Pure red cell aplasia in immunosuppressed transplant recipients.Case report

and literature review. 1 st Congres of the Romaniana Association of Medical

laboratories with International Participation, 24-27 June 2009, Tg Mures, Romania

abstract in Revista Romana de Medicina de Laborator.vol 15 nr 2 iunie 2009, pg 18

143. Mariana Patiu, Selicean Elena-Cristina, Filipas Cristina, Nastase Violeta,Cucuianu

Andrei: Pure red cell aplasia in immunosuppressed transplant recipients.Case report

and literature review. 1 st Congres of the Romaniana Association of Medical

laboratories with International Participation, 24-27 June 2009, Tg Mures, Romania

abstract in Revista Romana de Medicina de Laborator.vol 15 nr 2 iunie 2009, pg 18

144. Patiu M., Selicean C., Filipas C.,Nastase V., Cucuianu A. : Pure red cell aplasia in

immunossupressed renal transplant recipients. Case report and literature review. 1th

Congress of the Romanian Association of Medical Laboratories with International

Participation 24-27 june 2009 Tg Mures Romania, Abstract Published, . Revista Romana

de Medicina de Laborator, vol 15, nr 2, iunie 2009 supliment pg 18-19

145. Ciocanea C.I., Neagoe Berindan I., Balacescu O., Tudoran O., Balabescu L.,

Chiorean R., Irimie A., Cristea V. Molecular profiling of genes involed in angiogenesis

mechanism in ovarian borderline tumors using Agilent microarray technology,

Comunicata Medicalis Abstract Book, pag. 13, Cluj-Napoca, 14-17 may 2009.

146. Chiorean R., Balacescu O., Tudoran O., Balacescu L., Ciocanea C., Crisan N., Irimie

A., PCR Array analysis of angiogenic transcription profile in blood sample for prostate

cancer, Comunicata Medicalis Abstract Book, pag. 15, Cluj-Napoca, 14-17 may 2009.

147. Pileczki V., Kaucsar, T., Braicu C., Balabescu O., Cristea V., Irimie A., Optimization

of short interfering RNA (siRNA) trabsfection in Hs578T human breast cancer cell

lines for cancer therapy, Comunicata Medicalis Abstract Book, pag. 35, Cluj-Napoca,

14-17 may 2009.

74

148. Kaucsar T., Pileczki V., Braicu C., Balacescu O., Stugren C., Irimie A., Cristea V.,

Application of RNA interference in angiogenesis inhibition in breast cancer cell lines,

Comunicata Medicalis Abstract Book, pag. 36, Cluj-Napoca,14-17 may 2009.

149. M. Rusu, L. Krucz, C. Cenan, Gh. Sebestyen, T. Nicoara, N. Todor, G. Saplacan -

Home Health Care Units in telehealth systems, 5th Conference of the Eastern

Mediterranean Region of the International Biometric Society EMR-IBS, EMR-IBS

2009, ISBN 978-605-60615-0-9, p. 127, 10th -14th of May 2009 Istanbul, TURCIA

150. N. Todor, Ioana Brie, V. Foris, Nagy Viorica, M. Rusu, G. Saplacan: Evaluation

index for DNA lesions in comet assay, 5th Conference of the Eastern Mediterranean

Region of the International Biometric Society EMR-IBS, EMR-IBS 2009, ISBN 978-605-

60615-0-9, p. 256, 10th -14th of May 2009, Istanbul, TURCIA

151. Mircea Rusu, Gavril Saplacan, Gheorghe Sebestyen, Calin Cenan, Lorand Krucz,

Timotei Nicoara, Nicolae Todor: Distributed e-Health System with Smart Self-care

Units, ICCP 2009 Cluj-Napoca, ROMANIA

2010

152. T. Ciprian, S. Olga, P. Teodora, E. Fischer-Fodor, D. Rus Ciuca, B. Pintea, O.

Mosteanu, S. Susman, A. Irimie, G. Kacso: Arsenic trioxide sensitizes hepatocellular

carcinoma cells to conventional chemotherapy. Abstract Book page 49, Medicalis

2010- The 11th International Congress for Medical Students and Young Doctors, Cluj

Napoca, 13-16 May 2010.

153. G. Chereches, C. Tatomir, D. Daicoviciu, I.D.Postescu : Antioxidant Effects of A

Grape Seed Extract (GSE) ; The Pathobiology and Molecular Biology of Tumors,

International Conference, 28-30 apr.2010, Cluj-Napoca, Romania.

154. P. Virag, E. Fischer-Fodor, M. Perde-Schrepler, I. Brie, C. Tatomir. Cytotoxicity

and cytogenetic features of oxaliplatin resistant colorectal cancer cell line, Biology

and Therapy of Cancer Cell, “Prof. Dr. Ion Chiricuta” Oncology Institute International

Conference, First Conference of the Romanian Division of IAP (International Academy

75

of Pathology): “The Pathobiology and Molecular Biology of Tumors”, Abstracts book,

2, supple, 2010, 31-32.

155. I-C. Brie, V. Nagy, P. Virag, M. Perde-Schrepler, E. Fischer-Fodor, V. Foris, N.

Todor. Prediciton of clinical outcome in patients with cervix carcinoma by the pre-

therapeutic evaluation of DNA lesions, Biology and Therapy of Cancer Cell, “Prof. Dr.

Ion Chiricuta” Oncology Institute International Conference, First Conference of the

Romanian Division of IAP (International Academy of Pathology): “The Pathobiology

and Molecular Biology of Tumors”, Abstracts book, 2, supple, 2010, 32.

156. C. Tomuleasa, O. Soritau, T. Pop, E. Fischer-Fodor, B. Pintea, P. Virag, G. Kacso,

M. Acalovschi, A. Irimie. Arsenic trioxide sensitizes cancer stem cells to conventional

chemotherapy – a differentiation therapy model for hepatocellular carcinoma,

Biology and Therapy of Cancer Cell, “Prof. Dr. Ion Chiricuta” Oncology Institute

International Conference, First Conference of the Romanian Division of IAP

(International Academy of Pathology): “The Pathobiology and Molecular Biology of

Tumors”, Abstracts book, 2, supple, 2010, 45-46.

157. E. Fischer-Fodor, O. Soritau, P. Virag, R. Buiga, D. Pelau, C. Lisencu, O. Barbos,

N. Miklasova, Y. Schiffenbauer, A. Irimie. A static cytometry evaluation of the ex vivo

tumoral chemosensitivity to platinum-based drugs, Biology and Therapy of Cancer

Cell, “Prof. Dr. Ion Chiricuta” Oncology Institute International Conference, First

Conference of the Romanian Division of IAP (International Academy of Pathology):

“The Pathobiology and Molecular Biology of Tumors”, Abstracts book, 2, supple,

2010, 49-50.

158. C. Tomuleasa, O. Soritau, I. Brie, E. Fischer-Fodor, M. Perde-Schrepler, P. Virag,

V. Cernea, G. Kacso. Mesenchymal stem cell irradiation in culture engages

differential effect of hyperfractionated radiotherapy for head and neck cancers,

Medicalis, International Congress for Medical Students and Young Doctors, 13-16

May, Cluj-Napoca, Abstract book, 2010, 64.

159. T. A. Pop, C.I. Tomuleasa, O. Mosteanu, O. Soritau, B. Pintea, M. Achalovschi:

Efectul chimioterapiei, in vitro, cu trioxid de arsen, cisplatin/interferon alfa

76

2b/doxorubicina/capecitabina asupra hepatocarcinomului, Journal of

Gastrointestinal and Liver Diseases, Vol. 19, suppl 1, Al XXX-lea Simpozion national de

gastroenterologie, hepatologie si endoscopie digestiva, 2010, 165

Reprezentant legal


Manager




77

Anexa 5.3. Număr de modele, normative, proceduri

1x 5 = 5 pct

2005

1. Magdalena Patruleasa, Daniela Coza, Carmen Popescu, Adela Ratiu – Editia in limba romana a

Clasificarii Internationale a Maladiilor pentru Oncologie – Editia a treia – Publicatie a

Organizatiei Mondiale a Sanatatii si Ministerului sanatatii publice

Reprezentant legal


Manager




i ; i I i I i r

E i | | I i I i Ii i - - ! - ! I I i i - i - i

3 i ' l i : i : : i : 1 . | i l

r t _ : _ t , t t 1 1 1

i 3 i i ' I r ' t ii l i ' i t l l

r r r r r r l _ ] , _ L

t i 1 : t : t : t : t 1

l a l l - i i i I

: _ . : _ t - I 1 t 1 t I

n i i . t . l l - t - t . l

t l t 1 1 r 1 1 l

- t - i _ i _ i i - i - i : i _ i

3

. i - . i

_ 1 _ t t l

_ : _ : - i - l

- 1_ l _ - ! , l - -

I I _ :

- r ; : ; ; ; l

i i ii i I

iJi

;IT

T3

iR

I

B

f,!iE

E

A

I

3

i 3 i d E

i - i -

t f I2

:

Ea6

g

{

i t - - - - i - i t t l

i t - - " . i . t t i

, ^ 1 1 . " t " " - -i 1 : i " . i i i o i : : : : l

i . . i . . i t l " - t - - - - l

i t . i . -

i . , i " ; r ' i ; . ; i i l : i ; i ; : i i

_ _ l ' : _ : _ _ _ _ !

i i i i i = i , i .

. - : - - - - - , - l- t - . . t 1 - - r - - F - r i F

, _ i _ _ . - _ _ l _ _ _ 1 _ _ _ r _ , , - _ _ _ : _ _

- i - - _ - ; - i - - - i ; a - i : - : a ; ; - i - - :

1 t

1 l

i

I

6

I

;

; - i - - , , . - - ' - - i .

: i " : e : i Q : i 9 i 9 9 9 ? 9 e o 1 : " , : 9 i :

- i " . i . 6 i . i . " , _ " . " . . - i . i "

i i i t t t i ,i i l i i t i i

l - - - . i - .

i t l

r i i i iI I . t I i i i

! r ! i l l r I t t l

" . i " . " r " - i - i - - i " i . " . " J i " ; ; ; i ; t ; t ; li ; i J ; ; ; , i l , . i i - - i i ; i ; F ; ; ; ; ; ; ; ; ; l i i J i

- , ! - t . - - - l . t - t - . i - i - " - - , i . - - - . 1 - t - t - l

t l t t t t t ! t 'i i i t i t ii , i , , i - - - - - - - - - i - i

; i ; i ; i i ; i ; i ; i . , J i n ; l d d ; ; J " i ; i i ; ; i ; l i n

. i " . i - - i - i . i . . i " . i " . . - . 1 . . i " . - i - i " .

t t ii t i i i i t t i

_ L t - l _ t 1 1 1 1 L 1 ! _ _ : _ _ _ t _ : , 1 I- - i - - - t - - - t . - t - - - - - J - - - - - - i - l " l

" i - . t - - - | . | - | - l I - i - " - " . t . - - - . i - . i " l

i i i i t i i ,,. _ _ _ I _ _ _ i _ I _ I _ - ' 'i . t . t " J , . t " t " i " . i . . t - - - - i A - i " . . i . i " . l

i - . - " i i ' i i

- i t l 1 1 1 1 1 1 t _ _ _ _ ! _ _ i _ _ _ 1 , : I It . i . i - - i " l . i " . " " . J J . 1 " . " . i - . il ; i n l i ; ; i ; l ; i ; ; " : " : . i J ; ; l ; ; n ; i ; . i i

: . i - i , " i " . i , , - . , - - , , i " " i

" I - - - r . . . - - l - r -

r r : ' - - I - - I

i r i i l , ii i i l i l

i i . i - i ; - ; i : i - - - : - - - _ _ i - . . ,

" : ' i i , : - : , . r i

, i i l l t l. i i l i i l

i i i i i i t i i l

t t l l i t t t l

l t t t t i r ii i i i t i li i t i t l

i i t t t t t li , i - i - i ,

t ! i t i t l i I r i _ i _ i - l i

1 _ _ _ . t _ : _ _ _ . : _ _ _ - , f

l r f r r r r r _ : _ ] _ L _ 1 _

i i - - i - _

,

l t _ l _ t _ l _ l r r l l I l l r r r r

, j : d . ; i : : , 5 i 1 . " i ? ' 1 - l ; i ' . i . 5 t - :

I

l

L

IIIII

!i;

ga

c

Ia;ni 5

5 .

Tl t t t t lr i i i i

i i l t l

_ 1 I I l _ t _ i _ ] -l i " - i - i - i - l

r r _ t _ : _ 1 _ 1 _ 1 ,

1 _ t _ _ _ l _ 1 _ f _ f _ r -

1 r _ _ t _ : _ l _ i _ t _

I I r r 1 : _ _ ! _

_1_ i_ _ _. t _ t _ i - t - t

- i - i i . _ - i - i i : i _ i

9 { 9 1 9 9 9 1 9 t 9 1 9 1 9 1 !

{

I

i i i i I i i ai i i i i i i ;

I I ; i ; ; i i l ; i ; i ; i ; n n l ;

3 t | - t . - t - t " t - r - . t . . t -

t € . t . l . t - - t . t - i . - l - 1 .t 3 I t - l - l

i i l l - l " l - i " - i " t . l " . l . t .

i a r - i t " l - i

l t t I I I I l _ t _ : _ i _ : _ i _

n l | | i t l t i i .

l S t i | | I I I I i r "

w!p@M

Bilant - COD Ol - BILANT

TUL ONCOLOGIC .'PTof, DT, I.CHIRICUTA'' CLUJ-NAPOCA

2009

DaoalauI - furrxuldr r\dyurli!E

c ulmeaza a fi ncasat€ intr-o perloada mai mrca

INSTIT

Luna Raportar i i ; DECE14BER

http://ms.softeh.ro:88E8/oadFormulaxAsP.aspx

,t(apoftan lJUgeI Nnruslgru1 Danaldur - rurtrrud ^dpurldE

http://ms.soft eh.ro:8888/aILoadFormularASP.aspx

t

(.t,232+234+409+4!1:

omerclale/ avansur si alte de@ntari

.+411S+413+413+425+4282+4611+473**+2t 2p43.587 11583672

(d.232+234+409+4It+4113+413+413+461149113961): din Gre22 2843587 11583672

t32+234+409) 22,r 0

l+* + 431 ** + 4 4 24 + 442A+' + 444*+ + 4 4 6* r + 4 4a2

t664+4665+4669+431*++482'*-497) d a crel 23 0 0

4669-497)

ec L consol dat {ct,463 +464+465 +4664+46 6 5+0

u fonduriextern€ neramblBabies fondur de la

505+4507+4511+4513+4515+4531+4541+

t+4561+4563+4571+4572+4573+4531+4533+25

misla Euooeana (ct,4501+4503+4505+45071 26 0

469)

s.ud acordate (ct,2671+26t2+2673+26J 5+26J6

82+4533+4634+4635+4586+4687+4633+4539+27 0

3, t(ct.sos+595) 31 0 0

32

(ct,5l0+5121+5125+55201+5211+5212+52'523+5291+5292+529:5582+5591+5601+56(5142+5743+5744) din

a, alte valon, avansurldetrezorere31+5141+5151+5153+5161r5171+5187++ 5222 + 523 + 525 | + 5252+ 5253 + 526 + 527 +-5294+5299+5311+532+542+550 ta 557+5531++ 561 + 562+ 57 11 + 5J 12+ 57 13+ 57 14 + 57 47 +

2p39F49 469224

+ 5222 + 5642+ 5 t 14 + 57 4 4l 34 0

contu la hstitutli de cre{+5124+5125+5131+513t5171+5172+51S7+53141

llt, ca*, avansurlde hso€r e (ci.550+s112+s121r+5141+5142+5151+5152+5153+5161+5162+5411+5412+542+5533+5592+5601+5602) 35 1403362

+5602) 0 0

- 373S3S5

{cr.5126+5127+s187+5r01+s202+5203+5241+5242+s243)

6, 1 l 42 24045 8 5 1 8

J . TOTAL ACTWE CUREN 45

8, r5) 84SOO9t3 . 160m6593

30.01 .2010

,Raportai Buget Ministemll Sanatalii - Folmular Rapofiare

http://ms.softehro : 8888/aI-oadFormularASP.aspx

Page 3 of4

DATORIT 50

DATORII NECIIRENTE - sume ceumeaza afi plautedupa o perioada51

ceumeaza afi plante dupa operioada mai

101+403+4042+405+4622+509) d n care:52 7530

!4n3+4042+445+4622) 53

2.1662+1672+168-169)

l!ng (ct.1612+1622+1632+1642+1652+1661+

3. 0

:NIE (rd,s2+54+ss) 53 : . "i rrpo'

neceurmeaza afi platit€ Intr-o perloada de

1 (ct,401+403+4041+40

+5128) din Gre:

;+408+419+4621+471+481+482+483+269+509+60

dsu (ct, 401+403+4041+405+408+419+4621)61 9036498

0

2,

+46J2+4673+4674+4t

| 4 423 + 4 428 + 44 4 + 4 46 + 448 1 + 4 55 5 + 467 1 +

,5+4679+473+6i4s2) did cae:62 671919 1331166

(d- 43t+437+4423+4463 671919 1331166

1+437) $7534

i dln iondurl €xten€ nerambuEabrl€ (ct.4sss) 0

3, (d,4502+4s04+4506{

+4546+4552+4554+4:

fondurr externe neEmbursable sl fondu

:atre alte organlsme lntematonale

| 5t2+ 45 14 + 4 5 16 + 4 521 + 4 522 + 4 532+ 4 542 + 4544

i4+4584+453s+459+473+462+475)

0

759+462)

(ct.5186+5191+5192{

scurt - sume ce urmea4 a fi platite intr-o

t193+5194+5195+5196+s197+5198)70

0

5,

ung, sumeft urmeaza a f plalit€ in c!6u

1641+1551+1551+1662+1671+163,169)

o

6. ] saldill€ anqajatilor

+427r+428,, ]j2 | 1197917 968109

30.01 .2010

, .Raporta.ri

I

i Buget Mitri sanatata - f omular Kapo are

.+4213+429+434)0

)naj, bu6e (ct. 422+424+429) 73,1 0 0

8, ) 0

9_ 75 0 0

10,(rd.60+62+65+70+71

IE

72+73+ 14+?5) rxxxlawTOTAL DATORII (rd, 5l r78)

12,ACTIVE NEIE EIAI TOTAL\cnvE - TOTAL DATORII esal CAPTALURI PRoPRll

30

c.

1 (ct, 100+101+102+10:

+137+1391+1392+131

f 104+105+106+131+132+133+134+135+136

r+1394+1396+1399)

68419682 124492495

2, 85 9401831 I1726995

3, 0

dercltiului (d121 - sld creditor) 2322525 12112152

5. *r.mulul (d, 121 - so d debrtor) 88 0 0

6. PRII (rd,M+85-86+87-88)

r//ms.softeh.ro:8888/

(,<W':t--:-:,-al

ael.l!,t r) - \ . itre";,A*V\ \\

, AV\\\\

Vf\-.,\ftilffi

ormularASP.aspx 30.01.201http

ORJEPLATT

Cod de

Cod IBp6titol

D e h I

)Iry-IfoR r

L

AN

IE PLATA

-'fisr

r ' . F t: t I PLATlrl I:--"pt*lti;....-......"-...LJL ONCOLOCIC CLUI

4)4 t t t ) | eo*o

)6CLUJNAPOCA

..-.-- coi"r Brclilffiwffiffiffiffiffiilm

RO4OTREZ265001xxx006757 | I KxzKUbu

* t'lLri"ipiut Clul I'luPo"a

BENEFICIAR

Cod IBAN

17128123 Codul BIcNORMAL

!riourir&nsf.rurui T-l f-lRO73TR.EZo5otxxxoor865 lTRrzRoBU

LA i-tiwvunic,prutBucuesti

[5Ir;RE ARr 5 Pcr 7

D . i r c n ' r e F ' | / 2 3 u t t z o t u / l l ! - t t t . E 9 -| | ,i ! n ;. -' ..::'.| , . 7 l i l '

. - .V ! ] i * , 1 Y - r " '-s..rirGZ&fiftr"^fir,i sr;.etr{- v

iEn, , roor

)

raport de autoevaluare perioada: 1 iulie 2005- …...(lista brevetelor si cit ărilor, grupate pe...

Documents